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1. Introduction 
 
1.1. Abstract 
Background: We previously observed hypoglycemic episodes in preterm infants 
after achieving full enteral feeds and during a stable postnatal period. The purpose of 
this study was to prospectively determine subcutaneous glucose levels in this 
population. 
 
Methods: Twenty preterm  infants <32wks gestational age were enrolled for 
continuous subcutaneous glucose monitoring for 72hrs in two cohorts G1: <1000g 
BW (n=14) and G2: 1000–1500g BW (n=6). All infants were fed according to a 
standard feeding protocol where full feeds are provided at 150-180ml/kg/d of fortified 
EBM or premature formula at 110–135kcal/kg/d. Primary outcome was the frequency 
and quality of low tissue glucose episodes within 72 hours, defined as tissue glucose 
<45mg/dL. 
 
Results: 93% of the infants in G1 and 34% in G2 suffered glucose fluctuations 
during monitoring. Low tissue glucose episodes occurred in 21% in G1, compared to 
17% in G2. In G1 7% of infants in G1 reached glucose values <30mg/dL. We also 
observed high tissue glucose episodes (>150mg/dl) after feeds (G1: 50%, G2: 17%), 
followed by rapid drops in both cohorts. Cumulatively, all low- and high tissue 
glucose episodes lasted >60min (14%), 35-60min (21%), 10-30min (62%) and <5min 
(3%) per patient. The main risk factors for glucose instability were gestational age at 
birth and weight at trial. 
 
Conclusions: Otherwise stable, well developing former very low birth weight preterm 
infants are at risk for glucose instability, generally considered as unfavourable. It 
remains unclear whether this instability is likely to influence long-term outcome and 
whether continuous feeds are preventive. 
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1.2. Abstrakt 
Hintergrund:	   In einer vorangegangenen retrospektiven Studie wurden bei 
vollständig enteral ernährten Frühgeborenen mit adäquater Gewichtszunahme, eine 
erhöhte Inzidenz niedriger interstitieller Glukose-Wert Episoden festgestellt. In dieser 
prospektiven Studie wurden in der stabilen postnatalen Periode, kontinuierliche 
interstitielle Glucose Werte gemessen. 	  
Methoden: 20 Frühgeborene <32 SSW wurden rekrutiert und nach Geburtsgewicht 
in zwei Kohorten eingeteilt, G1: 500-999g GG (n=14) und G2: 1000-1500g GG (n=6). 
Die kontinuierliche interstitielle Glukose Messung erfolgte über 72 Stunden. Alle 
Kinder wurden nach einem Standard Bolus-Ernährungsprotokoll mit 150-180 ml/Kg 
verstärkter Muttermilch oder Frühgeborenen-Nahrung mit einer Energiezufuhr von 
110-135 kcal/Kg ernährt. Alle Kinder waren während der Studie klinisch stabil. Ziel 
dieser Studie war die asymptomatischen niedrigen- (< 45mg/dL) sowie erhöhte (>150 
mg/dL) interstitielle Glukose-Wert Episoden während 72 Stunden zu registrieren. 
 
Ergebnisse:	  93% der Frühgeborenen in G1 und 34% in G2 hatten Fluktuationen der 
Glucose-Werte während der kontinuierlichen Messung. Niedrige und erhöhte 
interstitielle Glukose-Wert Episoden waren häufiger und schwerwiegender in G1 
(21% vs. 17% und 50% vs. 17%). 7% in G1 erreichten Glucose Werte <30mg/dL, 
57% Werte >200mg/dL. Auf postprandiale hyperglykämische Peaks folgten rasche 
Glucose-Wert-Absenkungen. Die wichtigsten Risikofaktoren für die Glucose-
Instabilität waren Gestationsalter bei Geburt und Gewicht bei Studieneintritt. 
 
Diskussion: Klinisch stabile, adäquat wachsende Frühgeborene zeigen nach den 
ersten Lebenswochen ausgeprägte Schwankungen der Gewebe-Glukose-Werte. 
Diese Fluktuationen werden im Allgemeinen als ungünstig interpretiert. Es ist noch 
unklar ob diese metabolische Instabilität Konsequenzen für die spätere Entwicklung 
der Kinder hat und ob eine kontinuierliche Ernährung die Schwankungen verhindern 
könnte. 
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1.3. Background Information 
Glucose imbalances resulting in hypo- and hyperglycemic events during the neonatal 
period are an important problem as survival of the most fragile infants continues to 
improve. The estimated incidence of symptomatic hypoglycemia in full-term 
newborns is 1-3/1000 live births; the asymptomatic events are an unknown number 
[1, 2]. Regarding preterm infants, this incidence is even three times higher [3]. When 
it comes to hyperglycemia the incidence in term newborns is 20/1000 live births and 
450/1000 for preterm infants [4]. 
Neonatal hypo- and hyperglycemia correlate with brain damage and subsequent 
neurodevelopmental impairment. This has been well established by several research 
groups and studies [4-9]. Despite the evident vital importance of these clinical 
entities, it has not yet been possible to establish universally accepted definitions 
(either) for hypoglycemia or for hyperglycemia [10]. Each Neonatal Intensive Care 
Unit (NICU) has its own threshold to determine the accepted and tolerated glycemia 
levels in their patients. There is no general agreement regarding the definition of a 
safe limit for newborns. Each clinical situation has its own clinical management 
guidelines thus; the diagnosis and treatment of asymptomatic neonatal hypo- and 
hyperglycemic events require an individual assessment of each patient and situation.  
The objective of this prospective cohort study was to determine the incidence of 
silent hypoglycemias in fully enteral fed, clinically stable, former preterm infants. A 
Continuous Glucose Monitoring System (CGMS) – providing real time interstitial 
glucose values was used. Furthermore, the question was addressed as to whether 
tissue glucose fluctuations are related to a hypercaloric, preterm standard formula, or 
to the presence of other potential risk factors.  
So far no published reports have addressed this subject in preterm infants older than 
≥ 4 postnatal weeks [11]. There is one study by Staffler et al. in 98 infants with the 
same demographic characteristics as in this prospective study, showing an incidence 
of hypoglycemia of 44% in preterm newborns with a birth weight <1000g and 23% in 
those born with 1000-1500g [12].  
The fact that preterm newborns are metabolically unstable is well known. Therefore 
these children are closely monitored and their glucose metabolism thoroughly 
controlled to prevent the relatively frequent hyper- and hypoglycemic derails at this 
age. But after achieving full enteral feeds in apparently metabolic stable baby at a 
NICU on either supplemented breast milk or preterm formula blood glucose controls 
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are scarce. It is generally assumed that at this stage, without current risk factors 
apart from the former prematurity and low birth weight, the glucose concentration 
pattern does not fluctuate and is maintained within normal ranges.  
This study demonstrates for the first time that metabolic fluctuations between hyper- 
and hypoglycemic values since birth continue beyond at least the 32nd + 6 DOL and 
might have potential consequences for long time morbidity in these infants. 
 
 
1.4. Definition of Hypo- and Hyperglycemia: 
Hypoglycemia and Hyperglycemia represent an imbalance between glucose supply 
and utilization. These imbalances may result from a multitude of disturbed regulatory 
mechanisms, and mostly occur when the normal metabolic adaptation mechanism 
after birth fails [4, 13, 14]. There is no consensus in the medical community regarding 
the definition of either neonatal hypo- or hyperglycemia. Kalhan et al. refers to this 
controversy as “the inability to reach a consensus is because there is no absolute 
correlation between plasma glucose values, clinical symptoms and long-term 
sequels” [15]. In neonates there is not always a correlation between blood glucose 
concentration and the classical clinical manifestations of these entities. Thus clinical 
symptoms are not a reliable parameter to estimate blood glucose to be at an optimal 
level for maintaining e.g. brain metabolism. Additionally, if clinical symptoms of 
hypoglycemia are obvious in an newborn infant, the risk of neurological damage 
increases dramatically [16]. In 1988 Koh and colleagues addressed the controversial 
subject regarding the definition of pathological glucose levels in the newborn. Their 
results showed that among textbooks, guidelines and NICUs, the lower limit of 
normality for circulating blood glucose concentrations ranged from <18 mg/dL to 
<72mg/dL [14]. For hyperglycemia the values ranged from >120 -150mg/dL 
throughout >200mg/dL [4]. The thresholds depend upon the studied population, type 
(plasma or serum) and source (venous, capillary or arterial) of the blood samples, the 
methods of assay, feeding schedules of the measured infants and the type of 
nutrition they are receiving (breast milk or formula). This increased diversity of the 
variables only adds confusion to the subject [17]. Some authors propose a 
symptomatic definition of hypoglycemia, which depends on the presence of 
autonomic and /or neurological symptoms [10]. Other studies take into account an 
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additional definition correlating frequent previous hypoglycemic episodes and 
adverse long-term neurodevelopmental sequel and outcomes [11]. 
The definition of hyperglycemia remains equally unsettled and a symptomatic 
definition is almost impossible to make due to the lack of specific symptoms in 
newborn infants. At this point in time, there is no absolute safe lower margin for blood 
glucose level in newborns, because individual susceptibility as well as several 
different variables like duration, severity, cerebral blood flow, rates of glucose uptake 
and availability of alternative substrates during the event could individually determine 
poor neurodevelopmental outcome [18, 19]. In healthy term neonates blood glucose 
concentrations of 30mg/dL are common 1 to 2 hours after birth and are considered 
physiological and are well tolerated. These events are transient and asymptomatic 
and do not require treatment at all [19]. But this premise cannot be transferred to all 
newborns, because infants with risk factors do not tolerate the same glucose 
concentrations as well as healthy term newborns [11, 20]. Premature neonates have 
an immature control of glucose production and/or diminished substrate availability. 
This may be related to their prematurity, low birth weight- (LBW) or extreme low birth 
weight- (ELBW) or the fact of being small for gestational age (SGA). Other risk 
factors for hypoglycemia, which have a high prevalence in this specific group, are 
perinatal asphyxia and cerebral ischemia, hypothermia and infections [3, 15, 21]. 
Risk factors for term newborns are the administration of intrapartum glucose infusion 
to the mother and being offspring of mothers with diabetes mellitus or gestational 
diabetes [22]. 
Therefore, there is as yet no generally established and accepted clinical situation and 
glucose concentration that could be defined as the cut-off value for when to screen 
and eventually treat an asymptomatic episode. It depends on the patient, individual 
risk factors and the current clinical situation. 
After the first hours of life, the neonatal glucose concentration tends to rise to higher 
and stable values, in general >45 mg/dL by 12 hours after birth [19, 23]. But if the 
glucose concentration rises above normal parameters, into hyperglycemia, the 
neonatal risk increases yet again. Extremes, hypo- and hyperglycemic ranges are 
equally dangerous [6, 8, 9, 11, 24]. 
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1.5. Significance and Sequelae of Hypo- and Hyperglycemia 
Glucose is the brains primary essential energy substrate and it accounts for up to 
90% of the glucose-uptake in neonates [24-26]. Infants born during the critical rapid 
brain growth period between the 20th and 32nd gestational week postmenstrual age 
have most certainly a disturbed glucose homeostasis and therefore the highest risk 
for brain damage among the paediatric population [8]. Despite the confusion about 
the definition of hypo- and hyperglycemia it should be noted that there is no 
controversy regarding the deleterious effects on the brain due to a recurrent or 
persistent glucose imbalance during the neonatal and perinatal period [15, 24]. 
 
1.5.1. Consequences of Neonatal Hypoglycemia 
There is a correlation between glucose production and glucose consumption by the 
brain and the estimated brain weight at all ages. The brain uses about 20 times more 
glucose than muscle and fat and due to the infants’ large brain to body weight ratio 
(12% vs. 2% in adults) it results in a higher glucose turnover rate than in adults. 
Children with previous repetitive hypoglycemic episodes have a suboptimal head 
circumference (HC) and head growth, because if needed, cerebral structural 
substrates may become degraded to energy usable intermediates, resulting in 
decreased brain mass. These substrates may be lactate, pyruvate, alanin, glycerol 
and ketone bodies. They support brain metabolism, but at the expense of brain 
growth [5, 6, 24, 26, 27]. 
Lactate is, at this time, the best characterized alternative fuel. The cerebral lactate 
utilization rate correlates directly with the arterial plasma lactate concentration. Also 
ketone bodies (hydroxybutiric acid and acetoacetic acid) increase their concentration 
when plasma glucose concentration is low [21, 28]. Alternative substrates may be 
used by a variety of body tissues, decreasing their glucose demands and sparing it 
for the nervous system. Several studies have shown that the immature brain has a 
relatively greater tolerance to low glucose levels then a mature one and has the 
ability to use lactate and ketone bodies, the only alternative fuel able to cross the 
blood-brain barrier, partially decreasing the need for glucose. This is a protective 
mechanism against the deleterious effects of hypoglycemia on the central nervous 
system [24]. 
Several study groups have postulated other possible neuroprotective mechanisms 
like glycogen storage in astrocytes and increased cerebral blood flow during 
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hypoglycemic events, to ensure the glucose delivery which occurs via blood supply 
[6, 29-31]. It has also been demonstrated in several clinical studies that a clinically 
relevant hypoglycemia or a long lasting one has a direct proportional impact on 
neurological outcome [32, 33]. 
The pathogenesis and pathophysiology of the hypoglycemic damage is the 
correlation of low glucose concentrations with changes in cerebral blood flow, 
glucose uptake, oxygen consumption, intracellular energy and electrolyte changes. 
Hypoglycemia disturbs the cellular energy state, causing an energy failure, leading to 
necrosis by excitotoxicity. Glutamate accumulates and stimulates its receptors 
excessively, which triggers a calcium influx and potassium efflux causing the 
acceleration of proteolytic and lipolytic reactions culminating in apoptosis or necrosis. 
Reactive oxygen species (ROS) are also involved in causing neurological damage as 
a result of hypoglycemia, because this leads to an increased brain blood flow, 
causing a loss of autoregulation of the brain vessels, culminating in an oxidative 
stress, radical injury and cellular apoptosis [3, 18, 31]. 
Pryds et al. [30] recommend that blood glucose concentrations be maintained at 
more than 40-45 mg/dL to avoid cerebral hyperperfusion and epinephrine secretion. 
The epinephrine secretion indicates the activation of one of the brain protective 
mechanism to ensure its glucose supply. Among the neurological abnormalities seen 
on MRI (magnetic resonance imaging) of children who had symptomatic and/or 
asymptomatic neonatal hypoglycemic episodes are white matter alterations, white 
matter hemorrhages and different cortical injury patterns. The most frequent 
neuroimaging alteration involves the cortex and white matter of the parietal and 
occipital lobes. A large cerebral bleeding, regardless of its cause (hypo- 
hyperglycemia, prematurity or other), disturbs brain metabolism [25, 31]. 
Sixty-five percent of the infants in a study by Burns et al. [5] demonstrated 
neurological impairment at 18 months of age related to white matter injuries due to 
repetitive hypoglycemic events. The cognitive impairment of the infants was greater 
than the motoric one, showing low IQ-scores (< 86) at 5 to 7 years of age. 
Lucas et al. [11] reported reductions in Bayley motor and mental developmental 
scores at 18 months of age associated with repetitive episodes of neonatal 
hypoglycemia. The neurological deficits were not as striking at 8 years of age as they 
were at 18 months; but some impairment remained (in arithmetic and motor tests). 
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The permanent neurological impact of a low plasma glucose concentration in a 
particular infant is dependent on multiple factors: brain maturity, presence of 
ischemia and hypoxia, glycogen stores, presence of alternative fuels and genetically 
determined neural plasticity response [13, 16]. Some authors state that even a 
hypoglycemic episode of <47 mg/dL can have neurodevelopmental consequences 
like non febrile seizures, abnormalities in brain-stem auditory or somatosensory 
evoked potentials, isoelectric electroencephalogram (EEG) and even death [6, 7, 11, 
34, 35]. 
Apparently for some authors the decisive variable in the cause of brain injury is not 
the length and severity of a hypoglycemic event but rather the mere existence of one 
[5, 32]. The question that still arises is which glucose concentration causes brain 
damage and how long the event needs to be. Unfortunately at this point in time there 
is neither a correct nor a unanimous answer to it. 
 
1.5.2. Consequences of Neonatal Hyperglycemia 
In preterm infants, stress-reactive hormones such as epinephrine and norepinephrine 
increase in response to delivery, thermal instability, hypovolemia, low blood pressure 
and sepsis. These hormones and the often infused counterparts dobutamin and 
dopamine inhibit insulin secretion and action, promoting instead glycogen breakdown 
which could lead to hyperglycemia [33]. 
Several studies have demonstrated that hyperglycemia is an independent risk factor 
for neonatal morbidity and mortality. There is also a connection between high 
glucose concentrations, abnormal brain MRI scans and an increased incidence of 
intracranial hemorrhages. The elevated blood glucose concentrations cause a rise in 
serum osmolarity (every 18 mg/dL rise in glucose concentration results in an 
osmolarity rise of 1 mOsm/L)[1, 36], rapidly shifting water from the intracellular to the 
extracellular compartment, which may result in brain cell dehydration and capillary 
dilatation increasing the already elevated risk of cerebral hemorrhage in preterm 
infants. A further hazard is also the subsequent osmotic diuresis and polyuria with a 
possible consequential systemic dehydration. If cerebral bleeding occurs, the brain 
metabolism gets disturbed and a reduction in glucose consumption by the affected 
area follows. This again leads to hyperglycemia. Therefore, a hemorrhage could be 
the cause or the consequence of hyperglycemia.  As for the MRI scans, a reduction 
in white matter has been described, as well as an increased prevalence of 
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retinopathy in the preterm newborn with glucose values >155mg/dL, a higher 
incidence of sepsis and increased length in hospital stay. Experimental studies 
suggest that the pathophysiology in hyperglycemic events is an increase in oxidative 
factors, like in the hypoglycemic events. The excitotoxic injury of the brain cells 
produces brain damage [4, 8, 24, 25, 37]. 
 
1.6. Glucose Homeostasis in the Term, Preterm and SGA Newborn 
 
1.6.1. Metabolism in the Term Newborn 
Until the umbilical cord is clamped, there is no need for fetal glucose production 
during pregnancy [15, 24]. The glucose supply depends exclusively on the 
transplacentally glucose transport. The fetal glycemia is about 80% of the maternal 
glucose concentration with values oscillating between 70-90 mg/dL during a normal 
pregnancy. This ratio fetal – maternal glucose must be maintained at approximately 
2:3, because it provides the necessary gradient for the transplacentally glucose 
transport. Glucose crosses the placental membranes through facilitated diffusion, 
mediated by a carrier protein, GLUT3, which has the highest glucose affinity of all 
GLU- transporters. GLUTs are a family of glucose transporters, which, are located 
across the plasma membranes of cells and are structurally similar. Their expression 
is tissue-specific and the ontogeny of these transporters explains some of the 
metabolic differences between the neonate and the adult [28]. 
The transporters GLUT-1 and GLUT-3 are primarily expressed in the central nervous 
system and are responsible for the basal glucose uptake across the blood-brain 
barrier and into the neurons. GLUT-2 is predominantly expressed in hepatocytes and 
pancreatic β cells, has a low affinity to glucose, regulates the hepatic glucose uptake 
and release and is part of the β cell glucose sensor together with the enzyme 
glukokinase. In the placenta the predominant transporter is GLUT3. All these 
transporters are for the most part insulin independent. This means that the glucose 
uptake in those tissues is not affected by plasma insulin concentrations. In contrast, 
the GLUT-4 transporter, which is located predominantly in muscle, fat tissue and 
cardiac muscle, is an insulin-sensitive and dependant transporter [3, 4]. 
After birth, the residual fetal insulin precipitates a decline in plasma glucose 
concentration in the first neonatal hours. Not till then do the counter-regulatory 
hormones (epinephrine, glucagon, corticosteroids and growth hormone) suppress the 
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insulin dominance, favouring the induction of gluconeogenesis and allowing the blood 
glucose levels to rise by 3-4 hours of age [15, 28, 38]. This environment is a 
prerequisite to the induction of the hepatic synthesis of neural fuels: glucose (at a 
rate of 4-6 mg/kg/min) and ketone bodies [15]. The presence of ketone bodies in the 
blood is a good indicator of neonatal adaptation and that the insulin activity is being 
restrained or suppressed [39]. During this transition and adaptation to extra-uterine 
life, the newborn’s circulating glucose concentration may decrease to 30-40 mg/dL, 
because of the limited hepatic glycogen content, but the hepatic gluconeogenesis 
and ß-oxidation of free fatty acids (FFAs) via ketogenesis are activated within the first 
6-8 hours of life. These processes are essential for maintaining euglycemia. The 
gluconeogenic pathway is activated in the immediate neonatal period regardless the 
gestational age of the neonate, indicating that it is the birth process itself that 
activates the key gluconeogenic enzymes [3, 24, 40]. 
Metabolic adjustment and glucose stabilization in healthy full-term neonates can be 
expected after the first 4-72 hours of life [2, 7, 24, 38]. By that time in life an 
adaptation to the intermittent feeding with milk and a stabilization of the blood 
glucose levels may assumed. 
Even if enteral feeds are withheld, the hypoglycemic events in the first hours of life in 
an adequate for gestational age (AGA) term infant are self limiting and blood glucose 
concentrations rise rapidly to the metabolic demands of extrauterine life because of 
the counter regulatory metabolic response [7, 13, 24]. It has been shown that healthy 
term newborns have optimal metabolic management and maintain euglycemia during 
the alternating periods of enteral milk feeding and fasting [41]. 
 
1.6.2. Metabolism in the Preterm Newborn 
Metabolic adaptation differs for term, preterm and term/preterm SGA newborns. 
Immature neonates (24-29 weeks gestational age and birth weight between 600-
1200g) can produce glucose via glycogenolysis and gluconeogenesis at rates 
comparable to term newborns during their first DOL, but a certain functional 
immaturity of the enzymatic systems increases the propensity to hypoglycemic 
episodes [22, 24]. During the first postnatal week the relation between glucose and 
other metabolic fuels diverge among both groups because preterm infants have small 
body fuel stores and cannot sustain gluconeogenesis at the same rate as term 
newborns. The accumulation of glycogen, fat and protein occurs in the last 8 weeks 
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of pregnancy, and since premature infants are born before or during that time, they 
are not able to tolerate long periods of fasting [24, 28]. Blood glucose values show an 
increased variability in preterm infants. On one hand, the immaturity of the glucose 
sensor in the pancreatic β cell leads to an inability to down regulate insulin secretion 
during hypoglycemia: on the other hand, the hepatocytes do not respond accurately 
to the circulating insulin concentrations during hyperglycemia, instead continuing with 
their glucose production [4]. 
Preterm infants also have lower ketone body concentrations, even at lower glucose 
values, than term infants [42]. Glucose regulated insulin secretion (first detected at 
the 11th week of gestation, but not released until the 20th week) by the pancreatic β 
cell is still immature in preterm newborns, resulting in unregulated and inadequate 
insulin production and secretion. The plasma insulin concentration and the 
insulin/glucose ratio increase exponentially with gestation, indicating the maturation 
of the pancreas [22]. The relative lack of adipose tissue (<2% of total body weight) 
and glycogen stores in this group of neonates results in an incapability to produce 
alternative fuels to maintain euglycemia via glycogenolysis and gluconeogenesis for 
long periods of fast, causing a limitation for protective metabolic counterregulation 
during hypoglycaemia [28]. In preterm infants the endocrine and enzyme control of 
intermediate metabolism is immature and not fully developed, leading to a failed 
homeostasis. They are less able than term infants to adapt to cessation of 
intrauterine nutrition and they depend partly on total parental nutrition (TPN) during 
the first weeks of life [3, 4, 24, 42]. 
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Fig. 1.6.3.-1: Incidence of Neonatal Hypoglycemia by 
birthweight, gestational age and intrauterine growth. 
Reproduced with permission from Pediatrics, Vol.47 (5), 
Pages 831-8, Copyright © 1971 by the AAP 
1.6.3. Metabolism in the SGA Newborn 
Small for gestational age infants (SGA - neonates who fall below the 10th percentile 
for birth weight) have a higher risk for suffering transient hypoglycemia, have a higher 
mean blood lactate concentration and a lower mean ketone body concentration than 
AGA infants. This is also true for preterm SGA vs. preterm AGA babies, who have 
the lowest blood glucose and ketone body concentration among the 4 described 
categories of neonates most frequently present in a neonatal unit. Their disturbed 
homeostasis leads to a depletion of metabolic fuels predisposing to hypoglycaemia 
[20]. 
If extreme clinical conditions (e.g. sepsis, perinatal asphyxia and cold stress) occur 
concomitantly and demand 
more energy than available 
metabolic reserves, the 
overall risk for hypoglycemia 
increases even further [3]. 
Lubchenco et al [23] 
determined in 1971 the 
incidence of hypoglycemia in 
the first few hours after birth in 
newborn infants in a general 
obstetric service (Fig. 1.6.3.-
1). The SGA group shows the 
highest incidence of 
hypoglycemia, a result that 
many other authors have 
confirmed since and is an 
indicator for the inappropriate 
adaptation to the extrauterine 
life [20, 23, 24]. 
 
1.6.4. Enzyme maturation and glucose homeostasis 
Maturation of neonatal homeostasis is influenced by the integrity of specific pathways 
in the intermediary metabolism, which are more disordered with decreasing maturity. 
The activity of important enzymes participating in the gluconeogenesis, which don’t 
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increase their activity until the perinatal period [24], can make the first hours and 
days of life a difficult period for maintaining euglycemia. The insulin release at the 
20th week postmenstrual age, in response to elevated glucose concentrations may 
not be fully developed at birth and a relative unresponsiveness to insulin action may 
continue even in later development [43]. The hyperglycemic episodes are also more 
common in preterm infants due to the immaturity of the GLUT-system present in the 
hepatocyte and the pancreatic β cell [17]. The GLUT- 4 progressively increases its 
expression during gestation, coincident with the growth of insulin-sensitive tissues 
(skeletal muscle and adipose tissue) and the concomitant production and secretion of 
insulin into the blood stream. The effect of insulin causes the translocation of the 
transporter to the cell membrane and enhances the cellular glucose uptake, 
decreasing its blood concentration. If the transporter expression is low and the 
presence of insulin-dependent tissues, which express these transporters, is spare, it 
contributes to a peripheral insulin resistance with a diminished glucose uptake. 
The expression, function and/or sensitivity of GLUT-2 is decreased during gestation, 
therefore the insulin secretion in response to hyperglycemia in the perinatal period is 
diminished. There is also a persistent production of hepatic glucose despite elevated 
glucose values and significant elevations in plasma insulin. This is in part caused by 
the immaturity of the glucose sensor and in part by a decreased activity in other 
metabolic linkages in the β cell [1, 28]. It seems that the transporters are 
developmentally regulated and except for GLUT-1, which is abundant in fetal life and 
decreases after birth, the others appear to increase in number and sensitivity after 
birth, reaching adult levels later on in life [28]. 
During the neonatal and perinatal period, low insulin levels caused by an absolute or 
relative insulin insufficiency, a peripheral insulin resistance and/or inadequate 
responsiveness may lead to hyperglycemia. Preterm infants have an incomplete 
suppression of hepatic glucose production regardless of the circulating insulin 
concentration and concomitantly reduced peripheral glucose utilization [24, 44]. This 
decrease in the utilisation of peripheral glucose is partly caused by free fatty acids 
that alter the enzymatic activity, which preferentially leads to fatty acid carbon 
oxidation rather than glucose oxidation, promoting high glucose concentrations. Fatty 
acids also inhibit the effect of insulin on the suppression of hepatic glucose 
production. The insulin secretion is stimulated, but its action in the periphery is 
inhibited. The result is a peripheral glucose intolerance and central (hepatic) insulin 
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resistance, increasing the blood glucose concentrations. Other causes for 
hyperglycemic episodes are exogenous glucose infusions (which do not inhibit 
gluconeogenesis), the lipid component of the parenteral and enteral nutrition, 
physiologic stress in neonates caused by painful procedures, irritation during 
ventilatory treatment and catecholamine infusion, sepsis and some medications (e.g. 
theopylline, glucocorticoids, epinephrine, glucagon and fentanyl). To summarize the 
mechanism leading to hyperglycemia:  there is a decreased sensitivity to insulin and 
an excessive or inappropriate insulin secretion rate and plasma glucose production 
[4, 25, 37, 40, 45]. 
A decreased sensitivity to insulin has also been described in AGA or SGA preterm 
infants with a relatively normal rate of insulation secretion, even in those who have 
sufficient adipose tissue stores. Persistent hepatic glucose production at this age 
increases the risk of having insulin resistance, glucose intolerance and Diabetes 
Mellitus manifesting itself at adolescence and young adulthood [45-49]. 
 
1.7. Clinical Manifestations in Infancy  
 
A rapid decline in blood glucose concentration activates an autonomic response and 
causes neuroglucopenia, which may lead to neurological dysfunction. 
Table 1 - Clinical Signs and Symptoms of Hypoglycemia in Childhood[2] 
 
Features Associated with Cerebral 
Glucopenia  
 
Features Associated with Activation of 
the Autonomic Nervous System and 
Epinephrine Release 
Headache, Mental confusion Anxiety 
Visual disturbances Perspiration 
Organic personality changes Tachycardia, Palpitation 
Inability to concentrate Tachypnea 
Dysarthria, Ataxia, Aphasia Pallor 
Staring Tremulousness 
Paresthesias Weakness 
Dizziness Hunger 
Amnesia, Somnolence, Lethargy Nausea, Emesis 
Seizures, Stroke  
Hemiplegia  
Decerebrate or decorticate posture  
Coma, Death  
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The relation between low blood glucose values and clinical symptoms is relatively 
easy to observe in older children and in adults; but in newborns the signs are more 
subtle and too often asymptomatic [15]. The symptoms in newborns and infants 
include cyanosis, pallor, apneic episodes, tachypnea, hypothermia, hypotonia 
(floppiness), poor feeding, abnormal cry (weak or high-pitched), irritability, 
diaphoresis, tremors, jitteriness, exaggerated Moro reflex, lethargy and seizures. 
Some of these symptoms may be so mild that they are missed. It is of utmost 
importance to identify an event even in the absence of a correlation between low 
blood glucose concentrations and the presence of abnormal clinical signs [2, 7, 16, 
19, 21, 27, 28, 31, 50]. 
Most of the enumerated signs are not specific for hypoglycemia and can also be 
manifestations of other neonatal disorders (e.g. septicaemia, congenital heart 
disease, ventricular hemorrhage and respiratory distress syndrome), the common 
factor being poor peripheral circulation and tissue perfusion associated with 
hypoxemia and lactic acidosis [28]. To diagnose an event the index of suspicion for 
hypoglycemia must be high and other etiologies have to be excluded [4, 16, 19, 21, 
24]. 
Neonatal hyperglycemia is also mostly asymptomatic and possible signs are also 
indicative of other pathological processes. The symptoms include dehydration due to 
osmotic diuresis, weight loss, failure to thrive, fever, glucosuria, ketosis and 
metabolic acidosis [4]. 
 
1.8. Diagnosis of Hypo- and Hyperglycemia 
 
Routine monitoring is usually only performed in infants with risk factors during their 
first weeks of life at an NICU. Healthy full-term infants, born after entirely normal 
pregnancies and deliveries, which have no symptoms whatsoever, do not require 
blood glucose monitoring [35]. 
The presence of (1) clinical manifestations, (2) a reliable significantly low blood 
glucose value and (3) a prompt response to adequate therapy fulfill the requirements 
of Whipple´s Triad, the basis for making the diagnosis of significant hypoglycemia at 
any age. The problem arising with this “clinical diagnosis” is that most hypoglycemic 
episodes in the newborn patient are silent. Therefore, the latest guidelines from the 
American Academy of Pediatrics (AAP) [19] state that if either hypo- or 
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hyperglycemia are suspected, the plasma or blood glucose concentration must be 
determined immediately by using one of the laboratory enzymatic methods (glucose 
oxidase, hexokinase or dehydrogenase method). Plasma values tend to be 10-18% 
higher than whole blood values because of the plasma’s higher water content. If 
bedside methods are used (they allow a prompt diagnosis and initiation of therapy), 
the blood or plasma glucose concentration must be confirmed by laboratory methods. 
Although laboratory methods are the gold standard and the most reliable ones, their 
results may not be immediately available, relegating them to the confirmation of 
events [7, 19, 21]. 
In Neonatology, the incidence of hypo- and hyperglycemia depends on the criteria of 
diagnosis, the population surveyed, as well as the method for blood collection and 
glucose analysis [16, 31]. 
 
1.9. Management of Neonatal Hypo- and Hyperglycemia 
 
It is important to ensure in preterm and SGA infants an early provision of exogenous 
calories. If possible it should be enteral milk feedings, which enhance metabolic 
adaptation and gut maturation. In this specific demographic group the sucking reflex 
is not yet fully established: therefore, at first, feeding must be a continuous intra-
gastric infusion, if bolus feeds are not tolerated. If enteral feeding is not tolerated at 
all, an intravenous glucose infusion is indicated [51]. 
In term newborns, breast-feeding is encouraged and it should be on demand and 
unrestricted in duration and frequency. These babies are more likely to have low 
glucose levels but higher blood ketone body concentrations than artificially fed ones. 
If supplementation is needed, formula can be used, but it does not substitute breast-
feeding in any way [7, 13, 41, 42, 52]. 
 
1.9.1. Hypoglycemic Event Therapy  
If hypoglycemia is diagnosed in a symptomatic infant, regardless of the glucose 
value, a prompt intervention with an intravenous glucose infusion is required 
(“minibolus” of 200mg of glucose per kg, 2 mL/kg dextrose in 10% water). It rapidly 
corrects the hypoglycemic episode, without resulting in hyperglycemia. On the other 
hand, if the episode develops asymptomatic and it was an incidental diagnosis, with 
blood glucose concentrations of <45 mg/dL at the NICU Perinatal Center 
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Großhadern, the feeding frequency should be increased. If the episode is 
asymptomatic, but the glucose concentration is <36 mg/dL and the glycemia does not 
increase after a feed, or the infant develops abnormal clinical signs; an intravenous 
glucose infusion is needed. In either case, follow-up glucose concentrations and 
clinical evaluation must always be obtained for monitoring and control [7, 19]. 
The reasonable safe lower limit target value should be maintained at >45 mg/dL [21]. 
 
1.9.2. Hyperglycemic Event Therapy 
Hyperglycemic episodes need to be treated based on the infant’s diagnosis and 
suspected etiology. Potential dehydration, osmotic diuresis and serum electrolytes 
should be determined to calculate fluid therapy replacement. In the range 125-350 
mg/dL the gradual reduction of exogenous glucose administration should be 
sufficient to bring the glucose level back to normal. If severe hyperglycemia persists 
(>300-400 mg/dL), exogenous insulin administration may be needed, in the form of a 
continuous infusion beginning at 0.02 to 0.05 IU/kg/hour. With the addition of 
potassium the risk of hypokalemia can be minimized. Plasma glucose and serum 
potassium monitoring is advised (every 1 to 2 hours or whenever signs of 
hypokalemia and/or hypoglycemia develop), until achieving normoglycemia. The 
insulin-treatment is highly controversial among guidelines, experts and NICUs [4]. 
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2. Methods 
 
This doctoral thesis is based on a prospective observational cohort study with a total 
n=20 infants. Infants were enrolled at the Perinatal Center Grosshadern, Ludwig-
Maximilian University, Munich. 
We measured the interstitial glucose concentration continuously for three days in 
stable preterm infants who receive enteral high caloric nutrition according to 
guidelines [51]. The objective of this study was to diagnose the incidence of silent but 
clinically- relevant hypoglycemias and their correlation with high caloric feedings and 
other possible risk variables at about 30 DOL. 
Despite the fact that the protocol of our study has as its focus on the measurements 
with the CGMS and the results regarding incidence of hypoglycemic episodes and 
the possible variables affecting the metabolism of these infants, we decided 
retrospectively to look also at the charts of the included infants and to gather their 
blood glucose values obtained by capillary samples with the ABL-blood gas analyzer 
during their first ten days of life.  
Ethical approval was granted by the Ethics Committee of the LMU (2008.06.18) and 
informed consent was obtained from the parents for the inclusion of each infant in the 
study. The first infant was recruited and measured in April 2011 and the 20th in 
February 2012. 
 
2.1. Study Population 
 
All infants enrolled were born at the Perinatal Center, Grosshadern in the year 2011.  
The inclusion criteria were (1) birth weight < 1500g and (2) gestational age < 32 
weeks postmenstrual age. All infants were on full enteral feeds for a median of 26 
days and achieved a stable growth rate. 
The exclusion criteria were (1) a pathological outcome in the neonatal screening 
test on the 3rd day of life, (2) a positive family anamnesis for metabolic diseases 
besides Diabetes Mellitus and (3) acute congenital malformations. 
Between April 2011 and February 2012, of the total number of neonates born at the 
Perinatal Center, 213 infants were admitted in the NICU. Thirty-one percent of them 
were potential candidates for the study, but due to transfer to other facilities, ongoing 
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infections, received medication or the non-consent of the parents, only 30% of the 
potential candidates could be included and measured.  
 
2.1.1. Cohort distribution and characteristics 
Infants were classified into two cohorts. The first group (G1, n=14) had a birth weight 
<1000g, infants in the second group (G2 n=6) had a birth weight between 1000 -
1500g. The total number of included newborns for this thesis was n=20. 
Three infants were SGA-infants and were included in their respective weight-cohort. 
They all belonged to G1. Infants selected for this study were considered to be without 
major medical problems by the neonatologist in charge at the time of the 
measurements. 
 
2.1.2. Demographic Characteristics 
The following biomedical and perinatal information was collected: gestational age, 
gender, anthropometric values at birth, type of delivery, Apgar score at 1, 2, 5 and 10 
minutes, venous cord blood sample at birth, maternal obstetric history including 
complications and diseases (e.g. Diabetes Mellitus or Gestational Diabetes), 
reception of antenatal steroids, and neonatal problems and complications. 
Weight (g), length and head circumference (cm) and their corresponding percentiles 
were recorded again at trial entry, before, during and after measurements. For each 
infant the CRIB-Score (Clinical Risk Index for Babies, range from 0 – 23, higher 
score indicating more severe illness) [37] and Body Mass Index (BMI) [27] at birth 
were also calculated. 
On the Continuous Glucose Monitoring (CGM) – days, information about the energy 
intake and detailed data on nutrition and medication were collected, as well as on the 
7 days before and after the measurements. Other parameters and data like breathing 
support, occurrence of seizures, Bronchopulmonary Dysplasia (BPD), Intraventricular 
Haemorrhage (IVH) and Periventricular Leucomalacia (PVL) were also gathered. The 
diagnosis of grade I to IV IVH and PVL was determined through cranial 
ultrasonography (Logiq E9 Ultrasonography – General Electric’s Healthcare) by an 
attending neonatologist. 
Weight gain was calculated (g/kg/d) 7 days before and after measurement and the 
overall weight gain during hospital stay. 
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Regarding respiratory support (Table 3), 85% were receiving Continuous Positive 
Airway Pressure (CPAP), High Flow Nasal Cannula (HFNC) or alternated between 
both systems. 15% did not need any oxygen or ventilatory support during the CGM-
days. 
 
 
Table 3 - Details of Respiratory Support among Cohorts during the CGM-Days 
Cohort <1000g 1000-1500g 
n=20 14 6 
No Support (%) 7 33 
HFNC (%) 36 67 
CPAP (%) 21 - 
HFNC + CPAP (%) 36 - 
 
 
All infants received oral medications like vitamins and iron, 18 infants still received 
coffein base for the treatment of apnea and bradycardia episodes, 10 received 
fluconazol, 8 inhaled budesonid, 5 morphine, 4 phenobarbital, 3 teicoplanin, 
salbutamol, formoterol or ceftazidim and 2 were receiving erythromycin during the 
CGM-days. 
 
Table 2 - Baseline Characteristics of Infants at Recruitment 
Characteristics (Median + SD) <1000g 1000 -1500g P-Value * 
Total n: 20 14 6  
Gestational age at birth (weeks) 25.1 + 1.9 28.9 + 1.4 .002 
Birth weight (g) 640.0+ 165.8 1135.0 + 65.9 .000 
Gestational age at trial (weeks) 31.5 + 1.8 33.4 + 0.9 .207 
DOL at trial 48.0 + 14.7 32.5 + 6.0 .009 
Head circumference at trial (cm) 26.4 + 1.8 28.5 + 1.1 .020 
Length at trial(cm) 39.0 + 2.9 41.0 + 1.8 .051 
Weight at trial(g) 1362.5 + 209.4 1642.5 + 147.7 .012 
Sex n (%) male    13 (65%) 8 (57%) 5 (83%)  
CRIB score 7 + 3 1 + 1 .003 
BMI at birth 6,9 + 0.8 7,4 + 1.2 .009 
Arterial Cord blood pH at birth 7,36 7,38 .444 
Antenatal glucocorticoids (%) 86% 100% .659 
Mode of Delivery Vaginal 
                            Cesarian 
2 (14%) 1 (17%) .968 
12 (86%) 5 (83%) 
Total length of hospital stay (days) 69.0 + 17.3 61.0 + 14.2 .033 
* P < 0.05    
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2.1.3. Nutrition at birth and during the CGM-Days  
All children included in this study started enteral and partial parenteral nutrition on 
their first DOL. Initial enteral nutrition consisted of 8-12 meals of max 30ml/kg/day 
according to feeding tolerance. The energy intake was advanced daily, as 
recommended by guidelines, 110-135 kcal/kg/day. Nutritional composition was 10-
15% proteins, 40-45% carbohydrates and 30-35% lipids and essential fatty acids plus 
minerals (e.g. Iron) and vitamins (A, D, E and K) [53]. 
The goal for each preterm infant <1500g was to feed with breast milk fortified with 
human milk-fortifier FM85 (Nestlé®, Vevey, Switzerland) to meet nutritional 
requirements. If breast milk was not available or contraindicated, infants were fed 
with preterm formula (Beba FGN, Nestlé®, Vevey, Switzerland) plus LC PUFA (milk 
fortifier with long chain poly unsaturated fatty acids). Parenteral nutrition was 
increased daily to reach the nutritional recommendations of a total intake of 3.5 – 
4g/kg/day of proteins and 2.5 – 3g/kg/day of lipids, with the average energy intake of 
120 kcal/kg/day (European Society of Paediatric Gastroenterology and Nutrition 
(ESPGAN) and the American Association of Paediatrics (AAP)) [51]. The detailed 
nutrition characteristics are listed in Table 4. 
 
 
In G1 the median amount of days fully enteral fed at study entry was 25.0 days + 
16.7 and in G2 it was 20.5 + 5.3 days. During the 3-day measurement period, the 
received nutritional intake for all infants was as described in Table 4. One patient in 
G1 and two patients in G2 received sunflower oil (Mazola-Oil) as supplement. That 
nutrition enrichment is taken into account in Table 4. 
 
 
Table 4 - Feeding Characteristics of Infants on the CGM-Days 
Nutritional Intake (Median + SD) <1000g 1000-1500g 
Feeding volume (ml/kg/day) 151.2 + 13.6 153.2 + 8.2 
Energy intake (kcal/kg/day) 126.6 + 9.1 127.7 + 6.9 
Carbohydrate intake (g/kg/day) 15.7 + 1.8 15.5 + 1.5 
Protein intake (g/kg/day) 3.1 + 0.3 3.1 + 0.3 
Lipid intake (g/kg/day) 6.0 + 0.4 6.1 + 0.3 
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2.2. Data Collection and Test Methods 
 
2.2.1. Blood Glucose Sample Collection 
Intermittent capillary blood sampling by heelstick was routinely taken preprandial at 
least twice a week until the 35th week postmenstrual age. The samples were 
analyzed with an automated `Point of care blood gas analyzer (ABL 700´ 
Radiometer, Copenhagen, Denmark). The POC analyzer determines glucose value 
by an amperometric method. All blood glucose values taken during the selected 
infants´ hospital stay were recorded and analyzed. Blood glucose values within the 
first 10 DOL and those during the CGM-days were used to determine the presence of 
early fluctuations and to calculate the correlation between glucose values obtained 
from the ABL-analyzer and the continuous glucose monitoring system, respectively. It 
is important to remember that the whole blood glucose concentration is usually 10-
15% lower than the corresponding plasma glucose value [22]. 
 
2.2.2. CGMS Equipment Description 
Every enrolled child, once it was adequately full enteral fed, clinically stable and had 
reached at least its 30th gestational week postmenstrual age, was measured 
continuously for 72 hours. 
The device used for the CGM (Guardian® REAL-Time Continuous Glucose 
monitoring System, CGMS, Medtronic®, Northridge CA, USA) consists of a sensor, a 
transmitter and a receiver. The sensor (SOF-
SENSOR, Medtronic®, Northridge CA, USA) is 
minimally invasive, soft, flexible, disposable and is 
placed subcutaneously. 
This device is about 1mm in width, 10 mm in length 
and is mounted through a hollow needle. It has a 
platinum electrode which catalyses interstitial glucose 
oxidation, generating an electrical current every 10 
seconds. 
The sensor is connected to a wireless transmitter (MiniLink, Medtronic®, Northridge 
CA, USA), which provides power for the glucose sensor, collects data and transmits 
those to the receiver [54]. 
Fig. 2.2.2-1: Minilink Transmitter 
and Sof-Sensor. 
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The receiver (Guardian Monitor, Guardian® Real-
Time Continuous Glucose Monitoring System – 
Medtronic, Düsseldorf, Germany) records mean 
values every 5 minutes, 24 hours a day, providing 
288 interstitial glucose values per day. It displays the 
measured interstitial glucose level in real time on a 
screen together with graphic representation of the 
actual glucose pattern. Arrows indicate the direction 
and rate of change in the actual interstitial glucose levels. The device in this study 
was configured to alarm for low glucose levels (≤45 mg/dL) and displays the actual 
trends [55]. 
 
 
 
Fig. 2.2.2-2: Transmitter shown 
with a 50 cent Euro coin (24.25 
mm diameter) for size 
comparison. 
Fig. 2.2.2-3: Transmitter with charging device and receiver 
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2.2.3. Sensor Collocation and Removal 
After parental consent, the sensor was introduced subcutaneous into the lateral 
aspect of the infant’s thigh by the attending neonatologist under sterile conditions. 
The skin in the chosen area had to be intact.  
Before insertion, the chosen 
skin area was treated with a 
local anaesthetic patch, 
containing lidocaine and 
prilocaine (Emla® AstraZeneca 
GmbH, Wedel, Germany). 
In one of 20 infants a small 
amount of blood at the insertion 
site was observed and the 
sensor replaced. In all infants 
insertion site was inspected 
continuously by the nurse in 
charge. The whole procedure 
was well tolerated by all infants. 
There were no signs of irritation or inflammation of the skin in any infant throughout 
the study. The interstitial sensor takes two hours to stabilize after insertion before 
data recording starts. 
After the completion of the 3 days of CGM the attending neonatologist removed the 
sensor. Within a day after removal the puncture site at the thigh healed without 
residues in all infants [54]. In the weeks following the removal of the sensor, no infant 
showed any signs of infection or complications, which could be related to the CGMS. 
 
2.2.4. CGMS Calibration 
The CGMS system needs to be calibrated against POC blood glucose values two to 
three times a day to maintain its accuracy. Blood glucose values measured with a 
reflectance meter were discarded. 
If a hypoglycemic episode was measured (display showing an interstitial glucose 
value < 45mg/dL), a control whole blood sample of 50µL for glucose and 170µL for 
insulin were collected and sent on ice (+4°C) to the laboratory. The samples were 
Fig. 2.2.3-1: Sensor and transmitter inserted into the 
subcutaneous tissue 
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analyzed at the hospital clinical laboratory using the hexokinase method and an 
immunological method, respectively. 
 
 
2.3. Definitions, Statistical Methods and Analysis 
 
2.3.1. Operative Definition of low- and high Tissue Glucose Value Episodes 
Low tissue glucose value episodes were defined as an interstitial sensor glucose 
value ≤ 45 mg/dL (operational threshold at the NICU Perinatal Center Grosshadern). 
In order to determine the severity of these events, interstitial glucose values were 
ranked as described in Table 5. 
 
Table 5 – Tissue Glucose (TG) Value Classification 
Normal TG  > 45 mg/dl 
Moderate low TG 41 - 45 mg/dL 
Severe low  TG 31 - 40 mg/dL 
Extreme low TG < 30 mg/dL 
 
To define high tissue glucose value episodes, two values have been selected: 
>150mg/dL and >200mg/dL. These are the glucose cut-offs most frequently used in 
most publications, being >150mg/dL consistent with the renal glucose threshold and 
the observation of glucosuria in the preterm neonate and the commonly used value 
to define hyperglycemia in older children and adults and >200mg/dL the operational 
threshold at our NICU [1, 4, 8, 9, 25, 28, 36]. 
 
 
2.3.2. Statistical Analysis 
Data was analysed using the Statistical Package for Social Sciences 18.0 (IBM, 
SPSS Inc, Chicago, IL, USA). The level of significance was specified at P < .05. 
Since many of the measurement variables were not distributed normally, the median 
and standard deviations (SD) for each cohort were calculated and are the main 
measures reported. The statistical analysis was carried out with chi-squared tests to 
rule out any effect of confounding factors. To calculate the agreement between the 
paired samples obtained by the CGMS and those obtained by blood sample, a 
Related Samples Wilcoxon Signed Ranks Test was used and assessed by 
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Pearson´s correlation coefficient and a Bland-Altman method. The 95% confidence 
interval was determined with a two-sample T-Test. 
For the calculation of significance levels across cohorts the nonparametric Mann-
Whitney U Test or Kruskal Wallis Test were used. The positive and negative 
relationship between the different variables and the hypo- and hyperglycemic events 
are described with the Spearman’s rank correlation coefficient. 
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3. Results 
 
3.1. Correlation of capillary blood glucose and interstitial glucose 
concentration  
We calculated the correlation between paired glucose readings from capillary blood 
samples measured with the ABL-analyzer and the corresponding CGMS- interstitial 
glucose values. A total of 133-paired values were included in the analysis. The 
results were r=0.80, r²=0.68, p< .001 and the median difference between paired 
values equalled 0 mg/dL. The mean glucose difference between both monitoring 
systems was 0.48 mg/dL (95% confidence interval -2.80 to 3.66). The correlation 
remained excellent for lower glucose values (<150 mg/dL, r=0.81 and p = .000), with 
a mean glucose difference of -1.12 mg/dL between both methods, but the correlation 
decreased for higher ranges of values (>150 mg/dL). 
 
Figure 3.1-1: Accuracy of agreement between capillary glucose and CGMS-interstitial glucose 
values. 
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A Bland-Altman plot (difference plot) was made to illustrate the correlation and 
agreement between the two glucose-monitoring methods (Figure 3.1-2). 
The limit of agreement is set at + 2 SD (average difference + 2 standard deviations of 
the difference) 
 
 
 
 
The capillary glucose values used for calibration of the CGM-device were compared 
to the interstitial glucose values registered with the device. We took the ABL-value as 
“time 0” and compared it to the value registered by the CGM-device at 0, plus 5, 10, 
15, 20, 25 and 30 minutes. The best correlation coefficients were at 15 (0,488) - and 
20 minutes (0,489) after the blood sample was obtained.  
 
3.2. CGMS Data characteristics and results 
At study-entry, the median gestational age was 31.5 + 1.8 for G1 and 33.4 + 0.9 
weeks for G2. At that time 16 infants (80%) were fed with human milk + FM85 fortifier 
and 4 (20%) with preterm formula. 
A total number of 16874 subcutaneous glucose readings were recorded, which 
correlates with 1429 hours and 14 minutes of data. This means a number of 
measurements and record time per child of 844 + 78 and 71:27 hours + 6:49. 
Figure 3.1-2: Accuracy of agreement between the two methods (CGMS and capillary Glucose). 
Bland Altman graphical representation. M, mean 
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The highest and lowest median interstitial glucose values for n=20 were 190 mg/dL 
and 57 mg/dL. 
The median daily weight gain (g/kg/day) one week before the measurements was 
19.0 ± 15.2 (G1) and 36.8 ± 17,5 (G2) and one week after the completion of the 
CGM-days was 28.6 ± 8.9 (G1) and 41.2 ± 18.2 (G2). For these two variables there 
were no statistically relevant differences among cohorts. The overall median weight 
gain for each cohort during the entire hospital stay was 20.2 ± 4.3 (G1) vs. 25.4 ± 5.2 
(G2) g/kg/day (p = .044). 
 
Table 6 - Characteristics of Infants at CGM-Days  
Value (Median + SD) < 1000g 1000-1500g P-
Value* 
Gestational age at trial (weeks) 31.5 + 1.8 33.4 + 0.9 .207 
DOL at trial 48.0 + 14.7 32.5 + 6.0 .009 
Weight at trial (g) 1362.5 + 209.4 1642.5 + 147.7 .012 
Measured Time (hours) 71.5 + 8.2 70.67 + 1.25 .680 
Nr. of measurments/infant 849.0 + 94.0 829.0 + 15.0 .650 
Risk factors for hypo- hyperglycemia n (%) 
Prematurity 14 (100%) 6 (100%)  
Infant of mother with Diabetes Mellitus / 
Gestational Diabetes 
1 (7%) 1 (17%) .476 
SGA  3 (21%) .156 
Interstitial Glucose values (Median + SD and Range) 
Highest interstitial glucose 
concentration (mg/dL) 
210 + 64 (396-146) 136 + 26 (190-120) .004 
Lowest interstitial glucose concentration 
(mg/dL) 
54 + 15 (29-74) 57 + 11 (40-68) .648 
Nutrition at CGM-Days (nr. of infants and %) 
Fortified Human Milk (+ FM85) 13 (93%) 3 (50%) - 
Preterm Formula (Beba + LC PUFA) 1 (7%) 3 (50%) - 
Weight gain (g/kg/day)    
Daily weight gain 7 days before 
measurement 
19.0 + 15.2 36.8 + 17.9 
.284 
Daily weight gain 7 days after 
measurement 
28.6 + 8.9 41.2 + 18.2 
.219 
Overall weight gain during hospital stay 20.2 + 4.3 25.4 + 5.2 .044 
*P < 0.05    
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3.3. Prevalence and characteristics of Low- and High tissue glucose value 
events 
 
3.3.1. Prevalence and severity of Low- and High tissue glucose value events 
During the CGM-days, low tissue glucose value episodes (tissue glucose < 45 
mg/dL) were documented in 43% of the infants in G1 and in 17% in G2. All three 
SGA infants (G1) presented tissue glucose values within normal parameters during 
the 72 hours of measurement. 
The prevalence of high tissue glucose values overall (episodes with interstitial 
glucose values >150mg/dL) was 71% in G1 and 17% G2 (p= .028). Considering the 
threshold >200mg/dL, 57% of the infants (in G1) had severe high tissue glucose 
value events. In contrast, no infant in G2 had high tissue glucose value incidents with 
interstitial glucose values >200mg/dL (p= .020, table 7). 
Interstitial glucose values of some infants fluctuated between normal, high- and/or 
low ranges during the 72 hours of measurement. 
 
Table 7 - Metabolic Fluctuations among Cohorts during the CGM-Days 
Cohort <1000g 1000-1500g P-Value* 
n 14 6  
Normal TG Value (%) 7 66 .006 
Low TG Value Events (≤45mg/dL) (%) 21 17 .273 
High TG Value Events (>150mg/dL) (%) 50 17 .028 
Low - and High TG Value Events (%) 22 - .010 
* P < .0.05 
 
In total 93% of the infants in G1 and 34% in G2 had abnormal interstitial glucose 
values during the CGM-days (p= .010, figure 3.3.3-1.). The following graph illustrates 
the data in Table 7. 
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Figure 3.3.1-2 and 3.3.1-3 illustrate the relation between birth weight and the 
incidence of low interstitial glucose values. The pattern repeats itself for low birth 
weight and high tissue glucose values. The median highest interstitial glucose value 
was 210 in G1 and 136 mg/dl. The median lowest interstitial glucose value were 54 in 
G1 and 57 in G2. 
Figure 3.3.1-1: Tissue Glucose fluctuation within weight cohorts during CGM-days. 
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Figure 3.3.1-3: Infants with lower birth weight experienced higher TG values. 
 
Figure 3.3.1-2: Infants with lower birth weight experienced lower TG values. 
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Seven percent of the infants in G1 had tissue glucose measurements below 30 
mg/dL, 22% between 30 and 40 mg/dL, 14% had moderate low tissue glucose 
events of 41-45 mg/dL and 57% had interstitial glucose values >45 mg/dL. 17% in G2 
presented moderate low tissue glucose episodes with glucose values ranging 
between 41-45 mg/dL and 83% maintained normal tissue glucose values (>45 
mg/dL) as depicted in Figure 3.3.1-4. 
 
 
 
 
Figure 3.3.1-4: Incidence and severity of low tissue glucose events in each cohort 
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In G1 the overall incidence of high tissue glucose episodes (>150 mg/dL) was 71%. 
Only 29% of these infants were able to maintain glucose values below 150 mg/dL. In 
14% of infants from G1 we observed interstitial glucose values ranging between 150-
200 mg/dL, 57% had events with values >200 mg/dL. In contrast, only 17% of infants 
in G2 had moderate high tissue glucose episodes with interstitial glucose values 
between 150-200 mg/dL as shown in Figure 3.3.1-5. 
 
Figure 3.3.1-5: Incidence and severity of high tissue glucose events in each cohort 
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3.3.2. Length of high- and low tissue glucose episodes 
Of the 20 infants included in this study, only 5 (25% of the total) maintained their 
tissue glucose at all times. The rest suffered different long episodes of glucose value 
fluctuations. Figure 3.3.2.-1 illustrates the duration and severity of the total 241 
episodes in 20 babies recorded during their CGM-days. Twenty percent had at least 
≥ 1 episode of low tissue glucose (≤ 45 mg/dL), 40% had at least ≥1 episode of high 
tissue glucose and 15% suffered high- and low tissue glucose episodes during the 
CGM-days. Overall there were 14 low tissue glucose episodes among all infants. Six 
episodes lasted between 10-30 minutes and four lasted between 35-60 minutes. 
During the CGM-days there were 43 high tissue glucose events with glucose values 
>200 mg/dL, and they were only present in G1. Twenty-seven episodes lasted 5 
minutes and the rest of the episodes had a length of either 10-30 or 35-60 minutes. 
The high tissue glucose episodes with values >150 mg/dL were 184, of which 116 
lasted between 10-30 minutes, 39 lasted 35-60 minutes and 25 lasted more than 60 
minutes. The remaining episodes lasted a maximum of 5 minutes. 
 
Figure 3.3.2-1: Number and total duration of high and low tissue glucose episodes 
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3.3.3. Risk factors at birth and during CGM-Days for glucose homeostasis 
fluctuations    
Due to the currently small number of included infants in this study and their irregular 
distribution among cohorts (14 and 6), the significance of possible risk factors can 
only be preliminarily established. Based on the binary logistic regression analysis 
performed by Staffler et al [12], we included the same variables and added several 
more. The variables were: “gestational age at birth and at trial”, “carbohydrate, 
protein, lipid and energy intake at trial”, “length of parenteral nutrition”, SGA, BPD, 
BMI (Body Mass Index: birth weight / height²), CRIB-score and intracranial bleeding. 
At this point, none of the above mentioned variables showed a significant influence 
on the development of hypoglycemic events, neither for G1 nor for G2. 
On the other hand, there appeared to be an association between gestational age at 
birth (p= .020) and at trial (p= .033) with an elevated incidence of high tissue glucose 
value events. High tissue glucose value events are significantly more frequent in 
more premature infants (G1, p= .028). There is also a negative correlation between 
high tissue glucose value events and a smaller feeding volume in the group with high 
tissue glucose values (p = .033), lower protein and lipid intake (both in g/kg/day, 
Spearman’s-Rho ρ=-.526, p= .017 and ρ=-.589 and p= .006, respectively). But this 
correlation was only significant on the first (p= .014 and p= .024) and second day (p= 
.017 and p= .047) of monitoring. There was no significant correlation of protein and 
lipid intake and a higher incidence of high tissue glucose values on the third day of 
measuring. A positive correlation was established between high tissue glucose value 
events during CGM-days and the total length of the received parenteral nutrition (ρ= 
.639 and p= .003). The variables ICH/PVL also showed a positive correlation 
between them and repetitive high tissue glucose value events (ρ= .452 and p= .045). 
But when the U-Test was performed, the significance value was >.05, indicating that 
the intracranial bleeding incidence among infants who suffered repetitive high tissue 
glucose value episodes and those who did not was actually the same. 
SGA, BPD, low BMI and high CRIB score values did not seem to be predictable 
factors associated either with low- or high tissue glucose value events. We compared 
the BMI at birth with the metabolic patterns during the CGM-days and saw that 
infants who developed low- and high tissue glucose value events during the CGM-
days had a smaller BMI at birth (6.9 kg/m²) than those who only suffered high- (7.2 
kg/m²) or low tissue glucose value events (7.4 kg/m²), or those who remained with 
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their tissue glucose values within normal ranges (BMI of 7.7 kg/m²) during the CGM-
days. (Figure 3.3.3 -1) 
 
Regarding the CRIB score (graph 3.3.3 -2), the infants with the highest scores (mean 
value of 7.67) are those with abnormal tissue glucose values, which fluctuate 
between low- and high tissue glucose value episodes (Kruskal-Wallis-Test p= .049 
and Spearman Rho ρ= .496, p= .026), during the CGM-days. Infants with repeated 
low tissue glucose value episodes had the second highest CRIB scores with a mean 
value of 7.00. In third place, infants with high tissue glucose value episodes had a 
mean score of 6.25. Stable infants had scores below 2 points (mean score of 1.20). 
The different scores among infants who fluctuated during CGM-days can also be 
seen if we analyze the fluctuations during the first 10 DOL and again during CGM-
days with a significance of p= .016. 
Figure 3.3.3 -1: BMI at birth vs. the metabolic fluctuations experienced by the infants during 
CGM-Days 
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We could not detect any significant difference when considering the growth rates for 
weight (g/kg/day) seven days before and after the CGM-days, either among cohorts 
or when trying to relate them to low- and/or high glucose tissue value events. There 
is one significant difference among cohorts regarding the overall weight gain during 
the hospital stay, where G2 had a significantly higher weight gain than G1 (p= .044). 
We compared the characteristic birth weight, birth length and HC at birth with the 
incidence of low- and high glucose tissue values during the CGM-days and obtained 
one significant correlation (Figures 3.3.3-3, 3.3.3-4, 3.3.3-5). The HC at birth was 
significantly smaller in infants who afterwards, during the CGM-days, suffered 
repeated low tissue glucose value events (p= .002). When conducting the same 
calculations with the HC at trial, during the CGM-days, we could not determine any 
correlation. 
If we compare the anthropometric parameters at birth of the infants, which remained 
with tissue glucose values within normal ranges to those infants who fluctuated 
Figure 3.3.3 -2: CRIB score at birth vs. metabolic fluctuations during CGM-Days 
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during the CGM-days, we see significant differences for all three of them (birth weight 
p= .049, birth length p= .023 and HC p= .004). 
Weight and HC at trial vs. birth weight and HC at birth remain significantly different 
among cohorts. This was not the case for length at trial, but none of these 
parameters showed any correlation to a higher incidence of metabolic fluctuations 
during the CGM-days. 
 
 
 
Figure 3.3.3-3: Birth weight and tissue glucose fluctuations during CGM-Days 
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Figure 3.3.3-4: Length at birth and tissue glucose fluctuations during CGM-Days 
Figure 3.3.3-5: HC at birth and tissue glucose fluctuation during CGM-Days 
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3.4. Interstitial Glucose Pattern 
The interstitial glucose values obtained with the CGMS showed cyclic tissue glucose 
fluctuation within 24 hours according to the infants feeding schedule. The figure 3.4-1 
is derived from measurements in an infant who was receiving 8 bolus feeds per day. 
Figure 3.4-1: Glucose pattern of an infant with eight meals in 24 hours. 
 
The second figure 3.4-2 is derived from measurements in an infant who was 
receiving 12 bolus feeds per day. 
Figure 3.4-1: Tissue glucose pattern with 8 meals in 24 hours 
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Graph 3.4-3 shows an infant who received 6 meals per day and suffered repeated 
low tissue glucose values through to 40 mg/dl, in 24 hours. And graph 3.4-4 is 
derived from one of the 5 infants with tissue glucose values within the normal range, 
receiving 8 bolus feeds. In these five infants tissue glucose was independent of the 
number of meals they received per day (8, 10 or 12), and glucose stayed within 
normal limits in all infants (> 45 mg/dL and <150 mg/dL) at all times.  
 
Figure 3.4-3: Repeated low tissue glucose values in infant with six meals in 24 hours. 
 
 
Figure 3.4-4: Glucose pattern of a stable infant 
Figure 3.4-2: Tissue glucose pattern with 12 meals in 24 hours 
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3.5. Metabolic instability during DOL 1-10th and CGM-Days 
Many studies on neonatal hypo- and hyperglycemia describe these entities as a very 
common problem during the first 10 DOL in preterm infants [4, 9, 11, 23, 54, 56]. We 
recorded a total of 699 measurements, a median number of 35 ± 11 capillary blood 
samples per infant, performed over their first ten days of life. The median glucose 
value for G1 was 146 ± 23 mg/dL and for G2 110 ± 36 mg/dL. The maximum glucose 
values ranged from 279-136 mg/dL / 303-115 mg/dL in G1/G2 and the minimum 
values were 39-113 mg/dl / 59-87 mg/dL respectively. Only 21% of the infants in G1 
presented with a hypoglycemic event, with no relevant statistical differences among 
cohorts. 
In contrast, 100% of the infants in G1 and 50% of the infants in G2 suffered at some 
point during their first 10 DOL a hyperglycemic event of > 150 mg/dL. When 
comparing cohorts the difference reached significance (p= .004). And lastly, 
hyperglycemic events > 200 mg/dL were registered in 57% only in G1 (p= .017). 
Only 10% of the total number of infants remained euglycemic from their first DOL 
throughout the CGM-days. These infants belonged exclusively to G2. The rest of the 
infants had a derail in their glycemia at some point in time. 
The infants were classified into 4 categories. These are the infants who maintained 
normal tissue glucose throughout the measurement period (10%, belonging 
exclusively in G2), the ones fluctuating during the first days of life and again during 
CGM-days (70%) and finally those who only fluctuated whether during the first days 
of life (15%) or exclusively during the CGM-days (5%, also only in G2). 
 
Table 8 - Metabolic Fluctuations during the first 10 DOL and on the CGM-Days 
Cohort <1000g 1000-1500g P-Value* 
n 14 6  
Euglycemic (%) - 33 .026 
Fluctuation during first 10- and CGM-Days (%) 93 17 .026 
Fluctuation only during first 10 DOL (%) 7 33 >.05 
Fluctuation only during CGM-Days (%) - 17 >.05 
* P < 0.05 
 
The fluctuation (Table 8) was present in 93% of the infants in G1 during their first ten 
days of life and again on the CGM-days. This was also corroborated for 17% of the 
infants in G2. The rest of the infants in both groups had glycemia fluctuations only 
during their first 10 DOL or only during the CGM-days. 
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We compared birthweigth, length and HC at birth of the infants who reimained 
euglycemic during the entire hospital stay, with the values of the fluctuating infants. 
We obtained significant differences among the groups for all three variables 
(birthweight p= .022, birth length p= .028 and HC p= .044). The results are illustrated 
in figures 3.5.-2, 3.5.-3 and 3.5.-4. At trial entry, the weight, length and HC showed 
no relevant differences, nor any correlation with metabolic fluctuations. The overall 
weight gain during the hospital stay was significantly lower for the infants who 
suffered glycemia fluctuations during their first days of life and again during the CGM-
days (p= .032). The length of the hospital stay itself was the longest for the group 
who fluctuated at the beginning of their life and again during the period of continous 
interstitial glucose measurements (p= .030). 
 
Figure 3.5.-1: Incidence of metabolic fluctuations during the first 10 DOL and during  CGM-Days 
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Figure 3.5-3: Lenght at birth and metabolic fluctuations during the perinatal period 
Figure 3.5-2: Birth weight and metabolic fluctuations during the perinatal period 
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Figure 3.5-4: HC at birth and metabolic fluctuations during the perinatal period 
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4. Discussion 
 
In this study we determined for the first time that 85% of the infants in this study, with 
a median age of 48.0 days in G1 and 32.0 days in G2, were actually unable to 
maintain tissue glucose values within the normal range during 72 hours of CGM 
measurement. These glucose fluctuations during monitoring had a pattern of 
hyperglycemic episodes (>150mg/dl) after feeds, followed by rapid glucose drops in 
both cohorts. The main risk factors for glucose instability were prematurity, 
gestational age at birth and low weight at trial. 
 We employed CGMS to measure tissue glucose values. This technique was 
developed for diabetic patients to maintain tissue glucose within the normal limits 
during insulin therapy. However, CGMS have already been applied in preterm infants 
before. Comparing our correlation analysis results between the CGMS and the ABL-
Radiometer (r²=0.68, r = .827, p< .001) with the results obtained at this same NICU 
back in the year 2008, we can confirm the accuracy of the sensor measurements. 
The results in 2008 were r²=0.69 with p<0.05. Harris et al [57] reported a mean 
difference  of 0.0 mg/dL, 95% CI, -20 to 20, Beardsell et al. [54] a r²=0.87, p<.001, 
mean difference -11mg/dL, 95% CI -53 to 51, Garg et al. [3] a r²= 0.87, p<.001 and 
Iglesias et al [58]  r=0.96, p<.001) between different measurement methods using a 
CGMS in their studies. Their results are similar to ours. Therefore we can agree on 
an overall good correlation between the interstitial glucose values obtained with the 
CGMS and the corresponding glucose values obtained by capillary blood sample in 
this specific paediatric population [3, 37, 54, 57, 59]. 
When analyzing the time that shows the optimal accuracy between the blood glucose 
value and the interstitial glucose value, we determined the best concordance 
between 15 and 20 minutes after the blood sample was taken. This means that the 
CGM-device has a delay of 15-20 minutes in the representation of the blood glucose 
value. This is explained by the fact that the tissue has a buffer-capacity and it takes 
some minutes until the blood glucose has reached the interstitial space. When the 
sensor gives the alarm for increasing or decreasing tissue glucose values at a rapid 
rate, it means that the changes in the glycemia are happening or already happened. 
Our results agree with those obtained by Wackernagel et al. [60]. 
We compared glucose homeostasis of the same infants during their first days and 
after a few weeks of life, paying special attention to their glucose values as a 
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reflection of their metabolic stability and progressive maturation. In the early neonatal 
period, preterm infants are in a catabolic state, because their caloric intake is 
insufficient to satisfy their demands. After the conclusion of the neonatal period (per 
definition the first 28 days after birth), when all infants were medically stable, 
receiving an adequate full enteral caloric intake, and being ca. 48 (G1) and 32 (G2) 
days old, they should be in an anabolic state. We calculated the weight gain rates 
and obtained positive results for both cohorts. None of the infants lost weight, neither 
before nor after the completion of the continuous measurements, indicating the 
presence of anabolic processes (weight gain). 
When comparing both cohorts, the distribution of infants who received fortified breast 
milk (16) or preterm formula (4) was statistically the same and there were no 
significant differences between feeding volumes, energy intake and amount of 
carbohydrates, proteins and lipids received during their hospital stay. All infants were 
fed according to the ESPGAN guidelines [51]. All infants were partially parenteral fed 
initially. Each infant received an individualized feeding plan, based on gestational 
age, birth weight, clinical condition and mothers’ breast milk availability. The goal of 
the alimentation plan is to achieve a postnatal growth rate approximating intrauterine 
growth at the same postconceptional age [51, 61, 62]. Infants in G1 received more 
days of parenteral nutrition than the more mature infants (G2).They also took longer 
to reach full enteral feeds and they were hospitalized longer. Due to the overall 
immaturity of preterm neonates, the coordination of sucking, swallowing and 
respiration appears later in life (32-34 weeks of gestation). Until these reflexes 
appear, the nutrition must be partially parenteral to ensure an adequate energy 
supply and to prevent aspirations [61, 63]. During the first 10 days of life, the possible 
causes for the high incidence of low and/or high glucose events are well known, e.g. 
the overall physiological immaturity that is achieved later in postnatal life and the 
lipid, protein and glucose intake in the parenteral nutrition [17]. But the causes for the 
still metabolic instability at the time of the study, being fully enterally fed for a median 
of 25.0 ± 16.7 (G1) and 20.5 ± 5.3 (G2) days is a difficult to explain. At the time of 
measurements the nutritional goal to reach a total energy intake of ca. 110-130 
kcal/kg/day was achieved by all infants. None of the infants were overfed nor 
underfed, and all showed growth rates (weight, length and HC) according to their 
percentiles. 
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Despite the fact that there are significant differences between fortified breast milk and 
preterm formula (Table 4) regarding energy intake, carbohydrates, proteins and lipids 
content, this had no influence on the incidence of metabolic fluctuations during CGM-
days. There was no correlation of any of these parameters with the development of 
low tissue glucose events. When analyzing them for hyperglycemic events, there 
were three significant correlations. The high tissue glucose group had received a 
lower feeding volume and a lower protein and lipid intake on their first day of CGM, 
compared to infants who did not develop high tissue glucose values. When we 
analyzed the nutrition of the second day of CGM, there were no longer three 
significant correlations but only two (the lower protein p= .017 and lipid intake p= 
.047). And on the third day of CGM, the nutritional characteristics were the same 
across both groups (high glucose vs. normal glucose during CGM-days). The data 
about protein and lipid intake is very difficult to interpret, because of the impact of 
other possible cofounding variables in the ELGAN and VLBW infant [64].  
Our study has obvious limitations regarding its statistical power to explore 
correlations due to the small sample size, but the preliminary results show partial 
relevant nutritional variables (protein and lipid intake during CGM-days) that might 
influence glucose homeostasis of these former preterm infants. 
The CGM-device allows the detection of silent tissue glucose fluctuations in both 
directions that may go by undetected with the usual intermittent blood glucose 
controls every other day, routinely taken at the NICU, according to guidelines for 
clinically stable preterm infants [19]. This intermittent way of testing is recommended 
but it gives only a partial view of a constantly changing metabolic situation, which has 
been shown to be rather unstable in preterm infants [58]. The same guidelines also 
state that an infant should be able to maintain systemic glucose values within normal 
limits over several feed-fast cycles during the first ten DOL. It has been stated 
previously that later in postnatal life repeated glucose measurements are no longer 
needed [19, 65]. However, the glucose values we obtained during the CGM-days 
demonstrate that this presumed metabolic stability does not hold true for preterm 
infants under full enteral bolus feeds. In our cohort only 25% (5/20) of the infants, 
with a median age of 48.0 days in G1 and 32.0 days in G2, were actually able to 
maintain tissue glucose values within the normal range during 72 hours of CGM 
measurement. Of these stable infants only 1/5 was borne extremely preterm with a 
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birth weight below 1000g (G1). These findings imply that a major risk factor for 
metabolic instability is extreme prematurity.  
Since low- and high tissue glucose events are episodic and asymptomatic, only 
random blood samples in the exact right moment or a continuous measurement can 
diagnose them. In previous studies the percentage of hyper- and hypoglycemic 
infants varies enormously, depending upon the chosen thresholds, the studied 
population characteristics, especially their age and the particular guidelines regarding 
nutrition and frequency in glucose controls in each NICU. The primary objectives of 
most previous studies were the diagnosis, treatment and evaluation of sequels of 
neonatal hypo- and hyperglycemia within the first ten DOL. A few groups extended 
measurements up to six weeks of life [11], or even 12 weeks of life [1]. In these 
studies however the sampling rate in clinically stable and unremarkable infants was 
low. Our data illustrate that especially in high risk preterm infants occasional blood 
glucose sampling will underestimated the overall occurrence of low- and high tissue 
glucose value fluctuations 
Our findings regarding the incidence of hypoglycemic events in clinically stable, full 
enteral fed infants with a median age of ca. 48 (G1) and 32 (G2) DOL during CGM-
days (43% in G1 and 17% in G2), confirm our previous results from a retrospective 
analysis, indicating a high prevalence of silent hypoglycemic events (44% in G1 and 
23% in G2, p< .042) [12]. It is generally stated that glucose concentrations less than 
45 mg/dL are accepted during the first hours of life, glucose concentrations less than 
50-60 mg/dL afterwards are considered abnormal [3]. 
High tissue glucose value episodes during the neonatal period have not been as 
extensively researched as its counterpart, low tissue glucose value episodes. The 
publications on this subject state an increased morbidity and mortality for infants who 
suffer recurrent hyperglycemic episodes [4, 9, 25, 58, 66, 67]. Yet again, these 
studies refer mostly to the first days or weeks in the newborn’s life. To our surprise, 
the incidence of high tissue glucose value episodes (>150 mg/dL) for the infants in 
our study was 71% in G1 and 17% in G2 (p= .028). With glucose values >200mg/dL 
it affected 57% of the infants, predominantly in G1 (p= .020).  
These data suggests that ELGAN and VLBW infants are not able to adjust either 
insulin secretion or glucose utilization according to availability until reaching a 
specific gestational age. In previous studies it has been demonstrated that only at 
around 32 weeks postmenstrual age preterm infants are capable to adapt glucose 
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metabolism by secreting adequate amounts of insulin [43]. The infants in our study 
had reached a median age of 31.5 + 1.8 weeks of gestational age in G1 and 33.4 + 
0.9 weeks gestational age in G2 at the time of measurement. This could explain the 
higher fluctuation rate in G1 compared to G2.  
The presence of hypo- and hyperglycemic derails in the first hours, days and weeks 
of life is commonly associated with low birth weight, low gestational age, mother with 
gestational or pregestagional diabetes (requiring or not requiring Insulin) and being 
SGA among other variables. Wintergerst et al. [9] reported a hypoglycemia incidence 
of 18.6% (glucose values <65mg/dL) and a hyperglycemia incidence of 61% (>150 
mg/dL) / 35.2% (>200 mg/dL) in preterm newborns during their first 14 DOL. Lucas et 
al. [11] for his part published an incidence of 39% of infants <1000g with recurrent 
hypoglycemic events (<47mg/dL) during their first 3-30th DOL . Ten percent of them 
maintained these hypoglycemic episodes for more than 4 weeks of life. Lubchenco et 
al. [23] gathered the glucose values of preterm infants during their first 4 DOL, 
obtaining an incidence of hypoglycemia (<30 mg/dL) of 10% for AGA infants. This 
percentage was higher for SGA infants (25%). Alexandrou et al. [8] reported 
hypoglycemia in 41% and hyperglycemia (>150mg/dL) in 81% of his studied preterm 
infants in their first week of life. The results vary among authors, but a similar trend 
can be noted. Taking into account that these research groups focused on values 
during the first weeks of life in preterm infants and our results belong to infants with 
an median age of 48 (G1) and 32 DOL (G2), we can affirm that metabolic fluctuations 
described during the first days of life) continue after more than 4 weeks of life, 
despite clinical stability and full enteral feedings according to guidelines. 
In our cohort we were able to identify at least one risk factor (prematurity) for 
developing low tissue glucose values. However, no significant differences were 
detected with regard to perinatal risk factors comparing infants who developed tissue 
glucose fluctuations and those who remained within normal tissue glucose values. In 
G1 were the infants with lower birth weight (<1000g, p= .001), and concomitantly also 
with the lower gestational age (p= .004). These infants had low tissue glucose values 
more often in comparison to infants in G2.  
In our study most of the recurrent low- and high tissue glucose value episodes lasted 
for 10-30 minutes. Studies addressing the effect of high or low glucose episode 
duration on long term outcome are conflicting. Several previous studies indicated that 
repeated episodes of blood glucose values below 47 mg/dL (documented on 5 or 
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more separate days), whether they are symptomatic or not may impair 
neurodevelopment [11, 27, 68]. Others state that only prolonged hypoglycemic 
episodes are associated with neurodevelopment impairment and again others affirm 
that there is no clear correlation between duration or severity of the episodes and an 
abnormal neural outcome [5, 32]. Our study was not designed to shed light on this 
issue because a to small number of infants enrolled, thus further studies are 
required.  
Regarding the tolerance of the neonatal brain to extreme glucose values (whether 
they are hypo- or hyperglycemic), Salhab et al. reported that the immature brain is 
more resistant to the potential damages of low glucose values than the mature brain. 
He only takes into account glucose values during the first days of life and there was 
no follow-up, therefore the data is not conclusive [32]. With regard to high glucose 
values, Hays et al. and Sinclair et al. affirm that there is no reason to believe that 
ELBW infants should be more tolerant to high tissue glucose value than older 
children or adults [25, 69]. The dichotomy, why should be low tissue glucose levels 
better tolerated than high tissue glucose levels in preterm neonates or not and the 
involved risk of underestimating both extremes needs further clarification.  
Regarding the risk factors, the literature alludes only to their relevance merely during 
the first 10 DOL and after that, if no infection, hypoxia or ischemia is present, the 
glucose value controls are relaxed. During the CGM-days, none of the infants had 
ongoing infections or other potential variables that may have knowingly affected their 
glucose homeostasis. Our data confirm previous observations that extremely low 
gestational age infants are at risk to develop a failure to thrive, still present when we 
conducted our CGMS measurement [1, 11, 58]. This observation might be related to 
the increased risk of these infants to develop a metabolic instability late during their 
NICU-stay without apparent clinical signs and symptoms. The incidence of low tissue 
glucose value episodes is inversely related to birth weight and gestational age at 
birth, (G1) maintaining a higher frequency of metabolic instability even after 48 DOL 
during CGM-days than the infants in G2. Our current findings could not demonstrate 
a statistically significant association between low tissue glucose value episodes 
during the CGM-days and any of its well-known risk factors. Otherwise when it 
comes to high tissue glucose value episodes, a significant inverse relationship 
between gestational age at birth and at trial and can be made (p= .020 and p= .033).  
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We also found a correlation between high tissue glucose value episodes and a 
higher percentage of intracranial bleedings (Spearman’s Rho 0.452, p= .045), but 
without statistical significance when performing the Mann-Whitney U- Test (p>.05). 
These data are important and need further evaluation because despite being only a 
trend, it might prove valid in a larger cohort.  
Regarding the possible relation between a low BMI at birth and an increased 
incidence of low and high tissue glucose value episodes we observed the same trend 
as Lucas et al. [11] and Duvanel et al. [27]. We also determined that infants with 
fluctuating glucose values during the CGM-days had smaller BMI’s at birth than those 
who remained with their interstitial glucose values within normal ranges. Preterm 
newborns with recurrent episodes of glucose imbalance when compared to newborns 
with normal glucose values had a lower BMI. This finding is consistent with reduced 
glycogen and adipose tissue stores, an important factor that increases the propensity 
to metabolic instability in this specific demographic group [11, 27]. 
The Clinical Risk Index for Babies (CRIB score) assesses initial neonatal risk and 
compares performances among NICUs [70, 71]. We initially compared the mean 
CRIB scores among cohorts, and G1 showed significantly higher scores than G2. We 
also compared the risk index with the incidence of low and high tissue glucose value 
episodes and came to the conclusion that neither one had a significant correlation 
with the risk index. However, we did see that the infants with the highest scores were 
those who fluctuated between extreme tissue glucose values, not only during CGM-
days but also during their first 10 DOL and then again during the CGM-days. Hays et 
al [25] demonstrated in their study a significant relation between high CRIB scores 
and hyperglycemic events (>150mg/dL), although they only analyzed values of 
preterm neonates during their first week of life. In our study, we saw that the relation 
between a high risk score at birth and an increased incidence of metabolic 
fluctuations is still significant even after 4 weeks of life. 
It has been reported that infants with repeated hypoglycemic episodes have a 
smaller head circumference (HC) than euglycemic infants [27]. When we compared 
the following characteristics: birth weight, length and HC at birth with the incidence of 
high and low glucose episodes we observed a significant correlation between a small 
HC at birth and an increased incidence of low glucose episodes. If we compared the 
anthropometric values at birth of infants with normal glucose values to the values of 
the rest of the infants in the study we saw significant discrepancies. Infants who 
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suffered metabolic fluctuations during the CGM-days had the lowest weight, length 
and HC at birth. We could not determine any significance when comparing the same 
anthropometric values obtained at trial entry with a possible increased incidence of 
metabolic fluctuations. The stable infants, regardless of their cohort, always had the 
best values for weight, length and HC at birth in comparison to the anthropometric 
values of infants who suffered repetitive low- and/or high glucose tissue value events. 
These data indicate again that infants with extreme low birth weight, length and HC 
are at increased risk to develop metabolic fluctuations later during their NICU course. 
Duvanel et al [27] described a significantly smaller HC than expected in the follow-up 
controls of their study-infants who had suffered repeated neonatal hypoglycemic 
events. Follow-up data for this study are yet pending.  
The current feeding practice for neonates involves small frequent feedings (i.e. 8-12 
meals per/day, meaning every 3-2 hours). With the CGMS we obtained different 
glucose patterns, related to the feeding schedule in metabolically stable or instable 
infants. Infants with normal tissue glucose show very small fluctuations in response 
to bolus feeds (disregarding the number of feedings they received). Their metabolism 
is stable enough to control the secretion of insulin and its counterregulatory 
hormones, maintaining tissue glucose values within normal ranges at all times.  
The extreme glucose level variations may be caused by the immaturity of the 
metabolic pathways, not having reached optimal levels for hormone secretion despite 
the fact that these infants are already older than ca. 30 weeks gestational age, 
clinically stable and fully enterally fed. 
The observed glucose fluctuations could not only be related to a metabolic immaturity 
but also to concomitant variables like rates of gastric emptying [64]. Hunt et al 
determined that gastric emptying is independent of the initial volume and is rather 
determined by the nutritive density of the meal [72]. In addition, increased caloric 
density results in a slower gastric emptying [73]. Breast milk empties twice as fast as 
formula milk in preterm infants, but the whole process shows a large interindividual 
variability [74]. Since for both cohorts, during CGM-days, the volume and meal 
characteristics were equal, neither volume nor milk composition can be responsible 
for the different glucose patterns among infants. If we take a closer look at the 
patterns of the glucose fluctuating, those are exactly related to the number of bolus 
feeds. Consequently, the question arises if it would be better to switch to a 
continuous gastric feed scheme instead of boluses of milk and if this could prevent 
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the extreme glucose fluctuation. A meta-analysis of the available data concluded that 
that there is currently not enough evidence to determine which one of the feeding 
methods for low birth weight premature infants is better and no general 
recommendation on continuous feeding can be made [63]. 
When we compared the incidence of hypo- and hyperglycemic events during the first 
10 days of life to those obtained by other research groups we can see the same 
trend as those obtained by other authors. We only compared the data to those who 
had a similar demographic group, preterm neonates who are partially enteral / 
parenteral fed and without major clinical problems during their first days of life [3, 4, 
8, 9, 11, 23, 25, 28, 54, 56, 58]. Due to variations in birth weight, length of the 
analyzed period of time, the degree of stress, the type of nutrition received by the 
infants, and above all, the different thresholds considered as abnormal values, the 
incidences show some variations. The fact that 93% of the infants in G1 showed low 
and high glucose values repetitively during their first 10 DOL and again during the 
CGM-days, and that only this cohort experienced glucose values above 200 mg/dL 
demonstrates an inverse relation of metabolic fluctuations to gestational age and 
birth weight [24, 58].  Only 2 infants (10% of the total n) had normal glucose values 
during their first 10 days of life and again during CGM-days and they had a birth 
weight above 1000g (G2). In concordance with Hays et al., infants who developed 
high tissue glucose had a considerable longer hospital stay than those who remained 
euglycemic [25]. Previous studies describe the difficulties a term newborn has to go 
through, to achieve a stable postnatal glucose homeostasis and emphasises the fact 
that this process is much more difficult for a preterm newborn who has to add the 
major disadvantage of the immaturity of his metabolic pathways to the process [28]. It 
is very difficult for preterm to maintain their systemic glucose within normal limits 
postnatal. Without a glucose infusion preterm infants are at risk to slide into a 
hypoglycemic state due to their lack of energy stores (adipose and muscle tissue) 
and with a glucose infusion the risk of developing hyperglycemia increases [3, 20, 
24]. An additional difficulty of postnatal glucose control is the fact that in newborns 
the endogenous rate of glucose production is not suppressed by high concentrations 
of blood glucose values. The immature pancreas is also not able to secret adequate 
amounts of insulin to suppress gluconeogenesis, creating a relative peripheral insulin 
resistance [40]. In summary, the control of glucose production and suppression in the 
preterm infant is a complex process that is only partially controlled by insulin and 
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glucose concentrations. The overall degree of immaturity plays a central role in the 
pathophysiology of glucose instability in ELGAN- and VLBW infants [17, 24, 28, 75, 
76]. 
The glucose values of 70% of the total n=20 fluctuated into hypo-and/or 
hyperglycemia during the first days of life and again after ca. 4 weeks of life, during 
the CGM-days. It is much more likely that the fluctuations never ceased and were 
present all along, but because of the intermittent blood sampling went by undetected, 
rather than being present only during the first days of life, then stabilizing, and then 
reappearing at an average age of 48 DOL (G1) and 32 DOL (G2). The results agree 
with the concept that the metabolic transition from the complete dependence of the 
fetus to the complete independence of the neonate is a process, which takes time 
and continues for several months after the end of the neonatal period, reaching 
during infancy the developmental maturity necessary to switch to an adult-like 
glucose homeostasis [7, 17, 28]. 
Every infant is in a catabolic state after birth, showing a mean 10% decrease of 
bodyweight postnatal. Most infants regain their weight to birth weight within the first 
10 days of life. It is possible that some infants, due to their prematurity and to 
metabolic perturbations related to their immaturity need a few more days to regain 
their birth weight, like it happened to some of our infants in the study. Kalhan et al 
state that most of the growth parameters may remain subnormal after reaching a 
corrected gestational age of 40 weeks in high risk neonates [64]. This was not the 
case for our infants at the time of the study: with a corrected age of 31.5 ± 1.8 (G1) 
and 33.4 ± 0.9 (G2), they all remained within their percentile curves for weight, length 
and HC during the entire hospital stay, indicating that they received an adequate 
amount of calories and proteins. Since they had no intercurrent illnesses or stress at 
the time of the study, the best conditions were present for optimal growth. We do 
have to note that there were statistically significant differences regarding 
anthropometric characteristics when comparing metabolically instable infants, 
regardless if this was exclusively during CGM-days or during the first 10 days of life 
and again during CGM-days. Infants who presented an unstable metabolic state 
during the entire hospital stay had the worst anthropometric values (weight, length 
and HC at birth) of all infants. However, weight, length and HC at trial did not show 
any relevant correlation with the metabolic fluctuations. Regardless of the fact that 
the values remained within the normal percentiles for preterm newborns, the low birth 
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weight, length and HC were significant factors indicating an increased incidence of 
fluctuations during the first days of life and during CGM-days.  
Recent studies have linked low birth weight, gestational age and neonatal hypo- and 
hyperglycemic events during the first weeks of life with subsequent β cell dysfunction 
and impaired glucose tolerance, which manifest later in life [17, 47, 48, 77, 78]. There 
seems to be epigenetic changes and programming of different organ systems during 
development and there is an association between low birth weight and obesity, 
cardiovascular risk factors and insulin resistance of later onset [28, 48, 62, 79]. Since 
we concentrated on interstitial glucose values in infants who were much older than 
most of the infants in the published studies, we hope that with the metabolic follow-up 
at 4 and 8 years of age, we can gain information about the possible relation between 
hypo- and hyperglycemic events diagnosed during the neonatal period and beyond at 
an median age of 48 (G1) and 32 (G2) DOL and the development of a metabolic 
syndrome (obesity, insulin resistance, diabetes and cardiovascular disease) in 
adulthood. The velocity of weight gain might also be very interesting because some 
publications link a rapid weight gain during the first 4 months of life (corrected age) 
and during infancy with obesity in childhood and young adulthood [49, 78]. 
All 241 episodes of low and high episodes registered with the CGMS were apparently 
asymptomatic and clinically undetectable by the experienced NICU nursing staff and 
medical team. Clinical signs of disturbed neural function in the neonate and young 
infant are often too subtle to be recognized, but Koh et al. described abnormal 
changes in neural function in infants with glucose values below 47 mg/dL [68]. On the 
other hand Harris et al. induced hypoglycemic events in lambs with a simultaneous 
aEEG running and could not detect any changes in the measured parameters [80]. 
We will see if abnormal brain activity like subclinical seizure activity or transient 
neuronal activity deterioration was recorded during the hypoglycemic events in our 
study [17, 81]. 
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5. Conclusions 
 
The diagnosis of silent low and high interstitial glucose values is a very important 
subject due to the potential neurological impairment and metabolic consequences in 
preterm infants. The use of a CGMS is a feasible way of studying the dynamic 
glucose level variations in real time, in ELBW and VLBW preterm newborns. It is a 
harmless and almost low-risk method, which gives the maximum yield of information 
possible for an uncomplicated method. Only with a CGMS we are able to document 
the exact duration of an event and simultaneously diagnose and treat it. We have to 
take into account that due to the difficulty of patient recruitment for an invasive study 
in this specific population of infants, and due to the need to study the smallest 
number of subjects adequate to evaluate the proposed hypothesis adequately, this 
method has proven to be accurate and feasible. 
Up to date, an extensive number of studies have addressed the subject of hypo- and 
hyperglycemia and the long-term outcome in preterm neonates, but there is a lack of 
uniformity in the definition of hypo- and hyperglycemia, in the characteristics of the 
population studied and in the length of the follow-up controls, making it difficult to 
come to conclusive results. 
We expect this prospective cohort study to show potential correlations between the 
duration, number and severity of the suffered events during the entire hospital stay at 
the NICU and possible gravitating consequences at the 24 months Bailey test and 
the endocrinal checkups at 4 and 8 years of age. We have to wait for the follow-up 
control results to determine the impact of the described metabolic fluctuations and 
their connection to the development of a metabolic syndrome, diabetes mellitus and 
the functional impact of these problems at school age. 
 65 
III. References 
 
1. Pildes, R.S., Neonatal hyperglycemia. J Pediatr, 1986. 109(5): p. 905-7. 
2. Kliegman, R.M., Stanton B., St. Geme, J. et al, ed. Nelson Textbook of 
Pediatrics. Vol. 19th Edition. 2011. 655-668. 
3. Garg, M. and S.U. Devaskar, Glucose metabolism in the late preterm infant. 
Clinics in perinatology, 2006. 33(4): p. 853-70; abstract ix-x. 
4. Hemachandra AH, C.R., Neonatal Hyperglycemia. Pediatrics in Review, 1999. 
20(e 16): p. DOI: 10.1542/pir.20-7-e16. 
5. Burns, C.M., et al., Patterns of cerebral injury and neurodevelopmental 
outcomes after symptomatic neonatal hypoglycemia. Pediatrics, 2008. 122(1): 
p. 65-74. 
6. Vannucci, R.C. and S.J. Vannucci, Hypoglycemic brain injury. Seminars in 
neonatology : SN, 2001. 6(2): p. 147-55. 
7. Deshpande, S. and M. Ward Platt, The investigation and management of 
neonatal hypoglycaemia. Semin Fetal Neonatal Med, 2005. 10(4): p. 351-61. 
8. Alexandrou, G., et al., Early hyperglycemia is a risk factor for death and white 
matter reduction in preterm infants. Pediatrics, 2010. 125(3): p. e584-91. 
9. Wintergerst, K.A., et al., Association of hypoglycemia, hyperglycemia, and 
glucose variability with morbidity and death in the pediatric intensive care unit. 
Pediatrics, 2006. 118(1): p. 173-9. 
10. Gregory, J.W. and A. Aynsley-Green, The definition of hypoglycaemia. 
Bailliere's clinical endocrinology and metabolism, 1993. 7(3): p. 587-90. 
11. Lucas, A., R. Morley, and T.J. Cole, Adverse neurodevelopmental outcome of 
moderate neonatal hypoglycaemia. BMJ, 1988. 297(6659): p. 1304-8. 
12. Staffler A, K.M., Mola-Schenzle E,  Mittal R, Schulze A, Flemmer AW, Very 
low birth weight preterm infants are at risk for hypoglycemia once on total 
enteral nutrition. Journal of Maternal-Fetal and Neonatal Medicine. 2013 April 
17. (Epub ahead of print). 
13. Hawdon, J.M., M.P. Ward Platt, and A. Aynsley-Green, Prevention and 
management of neonatal hypoglycaemia. Archives of disease in childhood. 
Fetal and neonatal edition, 1994. 70(1): p. F60-4; discussion F65. 
14. Koh, T.H., J.A. Eyre, and A. Aynsley-Green, Neonatal hypoglycaemia--the 
controversy regarding definition. Archives of disease in childhood, 1988. 
63(11): p. 1386-8. 
 66 
15. Kalhan, S. and S. Peter-Wohl, Hypoglycemia: what is it for the neonate? Am J 
Perinatol, 2000. 17(1): p. 11-8. 
16. Cornblath, M. and R. Ichord, Hypoglycemia in the neonate. Seminars in 
perinatology, 2000. 24(2): p. 136-49. 
17. Cowett, R.M. and H.M. Farrag, Selected principles of perinatal-neonatal 
glucose metabolism. Semin Neonatol, 2004. 9(1): p. 37-47. 
18. Cornblath, M., et al., Hypoglycemia in infancy: the need for a rational 
definition. A Ciba Foundation discussion meeting. Pediatrics, 1990. 85(5): p. 
834-7. 
19. Adamkin, D.H., Postnatal glucose homeostasis in late-preterm and term 
infants. Pediatrics, 2011. 127(3): p. 575-9. 
20. Hawdon, J.M. and M.P. Ward Platt, Metabolic adaptation in small for 
gestational age infants. Archives of disease in childhood, 1993. 68(3 Spec 
No): p. 262-8. 
21. Rozance, P.J. and W.W. Hay, Hypoglycemia in newborn infants: Features 
associated with adverse outcomes. Biology of the neonate, 2006. 90(2): p. 74-
86. 
22. Cowett, R.M., ed. Principles of Perinatal-Neonatal Metabolism. Vol. 1. 1991, 
Springer-Verlag New York Inc. 1275. 
23. Lubchenco, L.O. and H. Bard, Incidence of hypoglycemia in newborn infants 
classified by birth weight and gestational age. Pediatrics, 1971. 47(5): p. 831-
8. 
24. Sunehag, A.L. and M.W. Haymond, Glucose extremes in newborn infants. Clin 
Perinatol, 2002. 29(2): p. 245-60. 
25. Hays, S.P., E.O. Smith, and A.L. Sunehag, Hyperglycemia is a risk factor for 
early death and morbidity in extremely low birth-weight infants. Pediatrics, 
2006. 118(5): p. 1811-8. 
26. de Lonlay, P., Giurgea I., Touati, G., Saudubray, J-M., Neonatal 
hypoglycaemia: aetiologies. Seminars in Neonatology, 2004(9): p. 49-58. 
27. Duvanel, C.B., et al., Long-term effects of neonatal hypoglycemia on brain 
growth and psychomotor development in small-for-gestational-age preterm 
infants. The Journal of pediatrics, 1999. 134(4): p. 492-8. 
28. Farrag, H.M. and R.M. Cowett, Glucose homeostasis in the micropremie. Clin 
Perinatol, 2000. 27(1): p. 1-22, v. 
 67 
29. Hawdon, J.M., Hypoglycaemia and the neonatal brain. European journal of 
pediatrics, 1999. 158 Suppl 1: p. S9-S12. 
30. Pryds, O., N.J. Christensen, and B. Friis-Hansen, Increased cerebral blood 
flow and plasma epinephrine in hypoglycemic, preterm neonates. Pediatrics, 
1990. 85(2): p. 172-6. 
31. Barkovich, A.J., et al., Imaging patterns of neonatal hypoglycemia. AJNR Am J 
Neuroradiol, 1998. 19(3): p. 523-8. 
32. Salhab, W.A., Initial Hypoglycemia and Neonatal Brain Injury in Term Infants 
With Severe Fetal Acidemia. Pediatrics, 2004. 114(2): p. 361-366. 
33. Hay, J.W.W., Strategies for Feeding the Preterm Infant. Neonatology, 2008. 
94(4): p. 245-254. 
34. Pildes, R.S., et al., A prospective controlled study of neonatal hypoglycemia. 
Pediatrics, 1974. 54(1): p. 5-14. 
35. Rozance, P.J. and W.W. Hay, Jr., Describing hypoglycemia--definition or 
operational threshold? Early human development, 2010. 86(5): p. 275-80. 
36. Dweck, H.S. and G. Cassady, Glucose intolerance in infants of very low birth 
weight. I. Incidence of hyperglycemia in infants of birth weights 1,100 grams or 
less. Pediatrics, 1974. 53(2): p. 189-95. 
37. Beardsall, K., et al., Early insulin therapy in very-low-birth-weight infants. N 
Engl J Med, 2008. 359(18): p. 1873-84. 
38. Srinivasan, G., et al., Plasma glucose values in normal neonates: a new look. 
The Journal of pediatrics, 1986. 109(1): p. 114-7. 
39. Mehta, A., Prevention and management of neonatal hypoglycaemia. Arch Dis 
Child Fetal Neonatal Ed, 1994. 70(1): p. F54-9; discussion F59-60. 
40. Chacko, S.K., et al., Gluconeogenesis is not regulated by either glucose or 
insulin in extremely low birth weight infants receiving total parenteral nutrition. 
J Pediatr, 2011. 158(6): p. 891-6. 
41. Hawdon, J.M., M.P. Platt, and A. Aynsley-Green, Neonatal hypoglycaemia--
blood glucose monitoring and baby feeding. Midwifery, 1993. 9(1): p. 3-6. 
42. Hawdon, J.M., M.P. Ward Platt, and A. Aynsley-Green, Patterns of metabolic 
adaptation for preterm and term infants in the first neonatal week. Archives of 
disease in childhood, 1992. 67(4 Spec No): p. 357-65. 
 68 
43. Montgomery, R.K., A.E. Mulberg, and R.J. Grand, Development of the human 
gastrointestinal tract: twenty years of progress. Gastroenterology, 1999. 
116(3): p. 702-31. 
44. Farrag, H.M., et al., Persistent glucose production and greater peripheral 
sensitivity to insulin in the neonate vs. the adult. Am J Physiol, 1997. 272(1 Pt 
1): p. E86-93. 
45. Rozance, P.J., Glucose metabolism in the preterm infant. The Journal of 
pediatrics, 2011. 158(6): p. 874-5. 
46. Singhal, A., et al., Low nutrient intake and early growth for later insulin 
resistance in adolescents born preterm. The Lancet, 2003. 361(9363): p. 
1089-1097. 
47. Yeung, M.Y., Postnatal growth, neurodevelopment and altered adiposity after 
preterm birth--from a clinical nutrition perspective. Acta Paediatr, 2006. 95(8): 
p. 909-17. 
48. Hales, C.N. and S.E. Ozanne, For debate: Fetal and early postnatal growth 
restriction lead to diabetes, the metabolic syndrome and renal failure. 
Diabetologia, 2003. 46(7): p. 1013-9. 
49. Stettler, N., et al., Rapid weight gain during infancy and obesity in young 
adulthood in a cohort of African Americans. Am J Clin Nutr, 2003. 77(6): p. 
1374-8. 
50. Hay, W.W., Jr., et al., How low can I go? The impact of hypoglycemia on the 
immature brain. Pediatrics, 2008. 122(6): p. 1411-2; author reply 1412. 
51. Agostoni, C., et al., Enteral nutrient supply for preterm infants: commentary 
from the European Society of Paediatric Gastroenterology, Hepatology and 
Nutrition Committee on Nutrition. Journal of pediatric gastroenterology and 
nutrition, 2010. 50(1): p. 85-91. 
52. Platt, M.P. and J.M. Hawdon, Hypoglycaemia in the neonate. Bailliere's clinical 
endocrinology and metabolism, 1993. 7(3): p. 669-82. 
53. Schulze A, F.A.W., Richtlinie für die enterale und parenterale Ernährung 
Neonatologie ( I-10A/B). 2007: p. 1-13. 
54. Beardsall, K., et al., The continuous glucose monitoring sensor in neonatal 
intensive care. Arch Dis Child Fetal Neonatal Ed, 2005. 90(4): p. F307-10. 
55. Wolpert, H.A., Continuous glucose monitoring--coming of age. N Engl J Med, 
2010. 363(4): p. 383-4. 
 69 
56. Holtrop, P.C., The frequency of hypoglycemia in full-term large and small for 
gestational age newborns. Am J Perinatol, 1993. 10(2): p. 150-4. 
57. Harris, D.L., et al., Continuous glucose monitoring in newborn babies at risk of 
hypoglycemia. J Pediatr, 2010. 157(2): p. 198-202 e1. 
58. Iglesias Platas, I., et al., Continuous glucose monitoring in infants of very low 
birth weight. Neonatology, 2009. 95(3): p. 217-23. 
59. Hay, W.W., Jr. and P.J. Rozance, Continuous glucose monitoring for 
diagnosis and treatment of neonatal hypoglycemia. The Journal of pediatrics, 
2010. 157(2): p. 180-2. 
60. Wackernagel D, D.M., Blennow  M , Tindberg Y, Kontinuierliche 
Blutzuckermessung bei Neugeborenen. Monatsschrift Kinderheilkunde, 
2012(1): p. 130. 
61. American Academy of Pediatrics Committee on Nutrition: Nutritional needs of 
low-birth-weight infants. Pediatrics, 1985. 75(5): p. 976-86. 
62. Hay, W.W., Jr., Strategies for feeding the preterm infant. Neonatology, 2008. 
94(4): p. 245-54. 
63. Premji, S.S. and L. Chessell, Continuous nasogastric milk feeding versus 
intermittent bolus milk feeding for premature infants less than 1500 grams. 
Cochrane Database Syst Rev, 2011. 11: p. CD001819. 
64. Kalhan, S.C. and S. Iben, Protein metabolism in the extremely low-birth weight 
infant. Clin Perinatol, 2000. 27(1): p. 23-56. 
65. Society, C.P., Screening guidelines for newborns at risk for low blood glucose. 
Paediatr Child Health, 2004. 9 (10): p. 723-729. 
66. Wintergerst, K.A., et al., Glucose control in pediatric intensive care unit 
patients using an insulin-glucose algorithm. Diabetes Technol Ther, 2007. 
9(3): p. 211-22. 
67. Hay, W.W., Addressing Hypoglycemia and Hyperglycemia. Pediatrics in 
Review, 1999. 20(7): p. 4e-5. 
68. Koh, T.H., et al., Neural dysfunction during hypoglycaemia. Archives of 
disease in childhood, 1988. 63(11): p. 1353-8. 
69. Sinclair, J.C., M. Bottino, and R.M. Cowett, Interventions for prevention of 
neonatal hyperglycemia in very low birth weight infants. Cochrane Database 
Syst Rev, 2011(10): p. CD007615. 
 70 
70. The CRIB (clinical risk index for babies) score: a tool for assessing initial 
neonatal risk and comparing performance of neonatal intensive care units. 
The International Neonatal Network. Lancet, 1993. 342(8865): p. 193-8. 
71. Buhrer, C., et al., The CRIB (Clinical Risk Index for Babies) score and 
neurodevelopmental impairment at one year corrected age in very low birth 
weight infants. Intensive Care Med, 2000. 26(3): p. 325-9. 
72. Hunt, J.N.S., D.F., Determinants of Gastric Emptying, 1974: Department of 
Physiology, Guy's Hospital Medical School, London S.E. 
73. Siegel, M., E. Lebenthal, and B. Krantz, Effect of caloric density on gastric 
emptying in premature infants. J Pediatr, 1984. 104(1): p. 118-22. 
74. Ewer, A.K., et al., Gastric emptying in preterm infants. Arch Dis Child Fetal 
Neonatal Ed, 1994. 71(1): p. F24-7. 
75. Tyrala, E.E., X. Chen, and G. Boden, Glucose metabolism in the infant 
weighing less than 1100 grams. J Pediatr, 1994. 125(2): p. 283-7. 
76. Putet, G., Lipid metabolism of the micropremie. Clin Perinatol, 2000. 27(1): p. 
57-69, v-vi. 
77. Hawdon, J.M., et al., Use of specific immunoradiometric assay to determine 
preterm neonatal insulin-glucose relations. Archives of disease in childhood. 
Fetal and neonatal edition, 1995. 73(3): p. F166-9. 
78. Hay, W.W., Jr., Nutrient supplies for optimal health in preterm infants. J 
Pediatr Gastroenterol Nutr, 2007. 45 Suppl 3: p. S163-9. 
79. Singhal, A., et al., Low nutrient intake and early growth for later insulin 
resistance in adolescents born preterm. Lancet, 2003. 361(9363): p. 1089-97. 
80. Harris, D.L., et al., Cot-Side Electroencephalography Monitoring is Not 
Clinically Useful in the Detection of Mild Neonatal Hypoglycemia. J Pediatr, 
2011. 
81. Hellström-Westas L, R.I., de Vries L.S, Greisen G, Amplitude-integrated EEG 
Classification and Interpretation in Preterm and Term Infants. NeoReviews, 
2006. 7(2): p. 76-87. 
 
 71 
Publikationen: 
Very low birth weight preterm infants are at risk for hypoglycemia once on total 
enteral nutrition 
Staffler A, Klemme M, Mola-Schenzle E, Mittal R, Schulze A, Flemmer AW. 
J Matern Fetal Neonatal Med. 2013 Sep;26(13):1337-41.  
 
Kontinuierliche Glukose Messung in enteral ernährten Frühgeborenen 
E Mola-Schenzle, A Staffler, M Klemme, A Schulze, KG Parhofer, AW Flemmer 
Diabetologie und Stoffwechsel 2013; 8 - P191 
 
Kontinuierliche Glukose Messung in enteral ernährten Frühgeborenen 
E Mola-Schenzle, A Staffler, M Klemme, A Schulze, AW Flemmer 
Monatsschrift Kinderheilkunde Supplement 1 2012; P130 
 
Preterm infants are at risk for recurrent glucose fluctuations while already 
stable and on full enteral nutrition 
E Mola-Schenzle, A Staffler, M Klemme, F Pellegrini, G Molinaro, KG Parhofer, H 
Messner, A Schulze, AW Flemmer 
Submitted for Archives of Disease in Childhood 2014 
 72 
IV. Acknowledgments 
 
I wish to express my sincerest gratitude to my supervisor, PD Dr. med. Andreas W. 
Flemmer, for giving me the framework to develop my doctoral thesis, and for his and 
Dr. med. Mathias Klemme’s unlimited support throughout the completion of this 
project. 
My thanks to the entire nursing staff at the NICU Großhadern and to the parents who 
willingly consented to their children’s involvement in the study. 
Thank you to my dear husband for his patience, invaluable discussion and first 
reading of this work. A special thanks to my parents and to Judith who read and 
corrected my English and to my entire family in Germany, Argentina and the States 
for their permanent support and generosity (morally and financially) during the 
completion of my thesis. 
